PCT

Hoboken, NJ 07030 (US).

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5: (11) International Publication Number: WO 92/06702 A1 A61K 37/00, C12N 5/00 (43) International Publication Date: 30 April 1992 (30.04.92) (21) International Application Number: PCT/US91/07443 (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent) (22) International Filing Date: 9 October 1991 (09.10.91) tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro-(30) Priority data: pean patent), NL (European patent), SE (European pa-599,802 19 October 1990 (19.10.90) US (71) Applicant: NEW YORK UNIVERSITY [US/US]; 550 **Published** First Avenue, New York, NY 10016 (US).

(74) Agent: BROWDY, Roger, L.; Browdy and Neimark, 419 Seventh Street, N.W., Suite 300, Washington, DC 20004 (US).

(72) Inventor: CHERKSEY, Bruce, D.; 608 Garden Street,

With international search report.

(54) Title: A METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USES THEREFOR

(57) Abstract

A method for grafting a cell in the brain of a mammalian subject is accomplished by attaching the cell to a support matrix so that the cell attaches to the matrix outer surface, and implanting the support matrix with the attached cell into the brain. Preferred support matrices are glass or plastic microbeads having a diameter from about 90 to about 125 µm. The method employs cells of different types, preferably cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT AU BB BE BF BG BJ BR CCF CG CH CI CM CS DE*	Austria Australia Barbados Belgium Burkina Faso Bulgaria Benin Brazil Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon Czechoslovakia Germark	ES FI FR GA GB GN GR HU IT JP KP KR LI LK LU	Spain Finland France Gaton United Kingdom Guinea Greece Hungary Italy Japan Democratic People's Republic of Korea Republic of Korea Liechtenstein Sri Lanka Luxembourg	MC ML MN MR MW NL NO PL RO SD SE SN TD TG US	Madagascar Mali Mongolia Mauritania Malawi Nutherlands Norway Poland Romania Sudan Sweden Senegal Soviet Union Chad Togo United States of America
--	---	--	--	--	---

⁺ Any designation f "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

A METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USES THEREFOR

BACKGROUND OF THE INVENTION

5 Field of the Invention

The invention in the field of neuroscience and medicine relates to methods for implantation or transplantation of cells into the mammalian brain, useful in treating neurological disorders.

10 Description of the Background Art

Grafting of neural cells and neuron-like cells directly into the brain may be a practical approach to promote recovery from debilitating diseases of the nervous system such as Parkinson's disease (PD), Huntington's disease

- 15 (HD), Alzheimer's disease (AD), epilepsy, and familial dysautonomia, as well as injury or trauma to the nervous system. The characterization of factors which influence neurotransmitter phenotypic expression in cells placed into the brain may lead to a better understanding of processes
- 20 involved in normal specification in the nervous system and indicate means by which birth defects resulting from aberrant phenotypic expression can be therapeutically prevented or corrected.
- Neurons or neuronal-like cells can be grafted into 25 the central nervous system (CNS), in particular, into the brain, either as solid tissue blocks or as dispersed cells. However, to date, a number of problems of both a technical and ethical nature have plagued the development of clinically feasible grafting procedures.
- Parkinson's disease (PD) results from a selective loss of dopaminergic nigrostriatal neurons, resulting in a loss of input from the substantia nigra to the striatum. Solid grafts of tissues potentially capable of producing dopamine, such as adult adrenal medulla and embryonic substantia nigra
- 35 (SN), have been used extensively for experimental grafting in rats and primates treated with 6-hydroxydopamine (6-OHDA) to

destroy dopaminergic cells (Dunn tt, S.B. et al., Brain Res. 215: 147-161 (1981); ibid. 229:457-470 (1981); Morisha, J.M. et al., Exp. Neurol. 84:643-654 (1984); Perlow, M.J. et al., Science 204:643-647 (1979)). Grafts of embryonic SN have also been used as therapy for primates lesioned with the neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), which produces a PD-like disease (Redmond, D.E. et al., Lancet 8490:1125-27 (1986)).

Stenevi et al. (Brain Res. 114:1-20 (1976), in in investigating the optimal conditions for neural graft survival, found that the best results were obtained when (a) fetal CNS neurons were used, and (b) the transplanted cells were placed next to a rich vascular supply. In fact, a review of the literature reveals that tissue from almost every area of the fetal brain can be successfully transplanted if care is taken with procedural details (see, for example, Olson, L. A. et al., In: Neural Transplants:

Development and Function, Sladek, J.R. et al., eds, Plenum Press, New York, 1984, pp. 125-165).

Embryonic tissue provides an excellent source of cells which will differentiate in a foreign environment and become integrated with the host tissue. For example, grafts of embryonic SN into 6-OHDA treated rats have been shown to produce dopamine, to reduce apomorphine- or amphetamine
25 induced rotation, to alleviate sensory deficits and to make synapses in the host striatum (Dunnett et al., Morisha et al., Perlow et al., supra). Grafted neurons are also spontaneously active, thus mimicking normal adult SN neurons (Wuerthele, S.M. et al., In: Catecholamines, Part B, (E.)

30 Usdin et al., eds.), A.R. Liss, Inc., New York, pp. 333-341).

In contrast to successful grafting of fetal neural tissue, mature CNS neurons have never been found to survive in transplants (Stenevi, U. et al., Brain Res. 114:1-20 (1976)). The reason fetal CNS neurons survive grafting procedures while adult neurons do not, while uncertain, is probably related to several factors. First, fetal neurons are less affected by low oxygen levels than mature neurons

(Jilek, L., In: <u>Developmental Neurobiology</u>, Himwich, W.A., ed., C.C. Thomas Publisher, Springfield, IL, 1970, pp. 331-369), and grafting procedures necessarily involve periods of anoxia until an adequate blood supply to the transplant is established. Secondly, fetal neurons seem to survive best when they are taken during a rapid growth phase and before connections are established with target tissues (Boer, G.J. et al., <u>Neuroscience 15</u>:1087-1109, (1985)). Also, fetal tissue may be especially responsive to growth (or "survival") factors which are known to be present in the milieu of the damaged host brain (Nieto-Sampedro, M. et al., <u>Science 217</u>:860-861 (1982); <u>Proc. Natl. Acad. Sci. USA 81</u>:6250-6254 (1984)).

However, despite the promise of fetal tissue and 15 cell transplants, the art has turned to alternate sources of donor tissues for transplantation because of the ethical, moral, and legal problems attendant to utilizing fetal tissue in human medicine. These sources include neural and paraneural cells from organ donors and cultured cell lines.

- 20 (See, for example: Gash, D.M. et al., In: Neural Grafting in the Mammalian CNS, Bjorklund, A. et al., eds, Elsevier, Amsterdam, 1985, pp. 595-603; Gash, D.M. et al., Science 233:1420-22 (1986)).
- Although early clinical experiments using the
 25 grafting approach did not result in long-lasting effects, an initial report of one study appeared more promising (Madrazo et al., Soc. Neurosci. Abstr. 12:563 (1986); for an overview, see: Lieberman, A. et al., Adv. Tech. Stand. Neurosurg.
 17:65-76 (1990), which is hereby incorporated by reference).
- 30 Several additional observations suggest that grafting adrenal cells should be a viable approach. Adrenal medullary cells are derived from the neural crest and, like sympathetic neurons, grow processes in vivo or in vitro in response to nerve growth factor (NGF) (Unsicker, K. et al., Proc. Natl.
- 35 <u>Acad. Sci. USA</u> 75:3498-3502 (1978)). Solid grafts of adrenal medulla from young rats can survive in the brain of 6-OHDA treated rats for at least 5 months, produce dopamine and reduce apomorphine induced rotation (Dunnett <u>et al.</u>, <u>supra</u>;

Freed, W.J. et al., Ann. Neurol. 8:510-519 (1980); Freed, W.J. et al. Science 222:937-939 (1983)). These observations suggest that given the appropriate environment, adrenal medullary cells have the potential for growing catecholamine-5 synthesizing fibers into brain tissue.

The potential for neuronal differentiation of chromaffin cells is even better elucidated by grafts of dissociated adrenal chromaffin cells which grow processes when injected into rat striatum. Cultured adrenal medullary 10 cells also differentiate into neuronal-like cells with processes when cultured in the presence of NGF (Unsicker, supra). This remarkable plasticity of adrenal cells is observed not only in morphology, but also in neurotransmitter phenotypic expression. An array of neuropeptides including 15 vasoactive intestinal peptide, as well as the monoamine, serotonin, are co-localized with catecholamines in adrenal medullary cells (Schultzberg, M. Neurosci. 3:1169-1186 (1978); Lundberg, J.M. Proc. Natl. Acad. Sci. USA 76:4079-4082 (1979)). Expression of these various phenotypes can be 20 modulated by extrinsic signals. For example, enkephalin and VIP expression are increased following denervation of the adrenal in vivo, by treatment of animals with nicotinic blockers or after maintaining adrenal cells in vitro (Tischler, A.S. <u>Life Sci.</u> 37:1881-1886 (1985)). 25 observations taken together with those of other studies demonstrating that neurons derived from the neural crest can switch phenotype during normal development (Bohn, M.C. et al., Devel. Biol. 82:1-10 (1981); Jonakait, G.M. et al. Devel. Biol. 88:288-296 (1981)) or following experimental 30 manipulation of the micromilieu (LeDouarin, N.M. Science 231: 1515-1522 (1986)) suggest that, in the future, it may be

by grafted cells either before and/or after grafting.

An additional advantage of grafting dissociated

35 cells compared to blocks of tissue is that the cells can be precultured with various substances such as growth factors prior to grafting or they can be co-grafted with other cells or substances which promote specific parameters of differen-

possible to control the neurotransmitter phenotype expressed

tiation. Furtherm re, glial cells may hav specific regional effects and produce neuronal growth factors (Barbin, G. et al., Devel. Neurosci. 7:296-307 (1985); Schurch-Rathgeb, Y. et al., Nature 273:308-309 (1978); Unsicker, K. et al. Proc. Natl. Acad. Sci. USA 81:2242-2246 (1984); Whitaker-Azmitia, P.M. et al., Brain Res. 497:80-85 (1989)). This suggests that co-transplanting cells providing the desired neurotransmitters along with specific types of glia which produce glial-derived factors, may promote neuronal growth and the desired differentiation of grafted cells.

Thus, the feasibility of the transplant approach has been established experimentally. However, this approach is severely limited by the need for the use of fetal tissue, which is of limited availability and of great political

- 15 consequence. In essence, transplantation of human fetal tissue from aborted pregnancies has been prohibited in the United States. It would thus be of great benefit if simple, routine and safe methods for the successful transplantation of adult tissue into the brain were available for the
- 20 treatment of debilitating neurological disease.

Aebischer and his colleagues have successfully implanted selectively permeable biocompatible polymer capsules into the brain which encapsulated fragments of neural tissue which survived in this environment (Aebischer,

- 25 P. et al., Brain Res. 448:364-368 (1988); Winn, S.R. et al.,

 J. Biomed Mater Res. 23:31-44 (1989). The polymer capsules
 consisted of polyvinyl chloride acrylic copolymer XM-50.

 Such permselective material completely prevented the invasion
 of the encapsulated tissue by host cells, and presumably
- 30 antibodies and viruses as well, based on the permeability of the membrane. When dopamine-releasing polymer rods were encapsulated into such a permselective polymer and implanted into denervated striatum in rats, alleviation of the experimentally induced Parkinson disease symptoms was
- 35 achieved (Winn S.R. et al., Exp. Neurol. 105:244-50 (1989). Furthermore, US Patent 4,892,538 (Aebischer et al., issued 1/9/90) discloses a cell culture device for implantation in a subject for delivery of a neurotransmitter comprising

secreting cells within a semipermeable membrane which permits diffusion of the neurotransmitter while excluding viruses, antibodies and other detrimental agents present in the external environment. The semipermeable membrane is of an 5 acrylic copolymer, polyvinylidene fluoride, polyurethane, polyalginate, cellulose acetal, polysulphone, polyvinyl alcohol, polyacrylonitrile, or their derivatives or mixtures and permits diffusion of solute of up to 50 kD molecular weight. This device is said to be useful in treatment of 10 neurotransmitter-deficient conditions, such as Parkinson's disease, by sustained, local delivery of neurotransmitters, precursors, agonists, fragments, etc., to a target area, especially the brain. The device may be made retrievable so that the contents may be renewed or supplemented, and the 15 cells are protected against immunological response and viral infection.

SUMMARY OF THE INVENTION

The inventors have made the unexpected discovery that by first culturing cells <u>in vitro</u> on a support matrix, 20 such as 90 μm diameter glass beads, such cells including mature CNS neurons or cultured cells, can be successfully transplanted into the mammalian brain. The beads, to which the cells adhere, are stereotaxically injected into the recipient's brain. Cells so injected retain their viability 25 and are thus effectively transplanted. They show prolonged survival and viability <u>in vivo</u>, even when transplanted across species barriers.

It is an objective of the present invention to overcome the aforementioned deficiencies in the prior work.

- The present invention provides a method for grafting a cell in the brain of a mammalian subject comprising culturing the cell with a support matrix so that the cell attaches to said matrix, and implanting the support matrix with the attached cell into the brain.
- The method includes support matrices made of glass and other silicon oxides, polystyrene, polypropylene,

polyethylene, polyacrylamide, polycarbonate, polypentene, acrylonitrile polymers, nylon, amylases, gelatin, collagen, natural and modified polysaccharides, including dextrans and celluloses (e.g. nitrocellulose), agar, and magnetite.

5 Preferred support matrices are beads, in particular microbeads having a diameter from about 90 to about 150 μm .

The method of the present invention may employ cells of many different types, preferably either cells of neural or paraneural origin, such as adrenal chromaffin

- 10 cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following transfection with DNA encoding a neuropeptide or an enzyme or set of enzymes which results in production of neurotransmitter, or a neuronal growth factor.
- The present invention includes a method for treating a neurological disease in a subject which comprises grafting an effective number of cells capable of treating the disease according to the above methods. Diseases which can be treated according to the present invention include, but
- 20 are not limited to, Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, familial dysautonomia, and traumatic brain injury.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photomicrograph of a section of the 25 brain of a rat implanted with adult adrenomedullary cells on a glass microbead. The section was fixed an stained histochemically for tyrosine hydroxylase (TH) using horse radish peroxidase. The darkly stained areas indicate cells containing TH. The pattern of staining shows a needle tract 30 entering the section on the right side. The large circular stained area in the center represents the bulk of the implanted cells. Te injected cells form a "gland-like" pattern, with some extending back into the needle tract. (Thickness: 20 microns; magnification: 100x)

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is based on the unexpected discovery by the inventors that adult cells or cultured cells which cannot normally be transplanted into a mammalian brain and survive, can be made to survive by first attaching them to a support matrix.

A number of different cell types are useful for the present invention. Typically, a cell will be selected based on its ability to provide a missing substance to the

- 10 recipient brain. Missing substances can be neurotransmitters or other neurally-active molecules, the absence of which results in neurological disease or dysfunction. It is important that the transplanted cell not grow as a tumor once it is inserted into the recipient.
- The references cited below are all incorporated by reference herein, whether specifically incorporated or not.

By the term "neural or paraneural origin" is intended a cell which is derived from the embryonic neural crest. A preferred example of a cell of paraneural origin is

- a adrenal medullary chromaffin cell. The precursor cells to the mammalian adrenal medulla are of neural crest origin and possess the potential to develop along either neuronal or endocrine lines of differentiation (Bohn, M.C. et al., 1981, supra, Devel. Biol. 89:299-308 (1982); Unsicker, K., Develop.
- Biol. 108:259-268 (1985)). Chromaffin cells from the rat, monkey, and human adrenal medulla, when removed from adrenal cortical influences and exposed to nerve growth factor (NGF), change from an endocrine to a neuronal phenotype (Notter, M.F. et al., Cell Tiss. Res. 244:69-70 (1986); Stromberg, I.
- 30 et al., Exp. Brain Res. 60:335-349 (1985); Unsicker, K. et al., 1978, supra). When co-grafted with cerebral cortical or hippocampal tissue into the anterior chamber of the rat eye, adrenal chromaffin cells form nerve fibers which innervate the adjacent co-grafted brain tissue (Olson, L. A. et al.,
- 35 Exp. Neurol. 70414-426 (1980)). Another paraneural cell type is a retinal pigment epithelium cell (Song, M-K et al., J. Cell. Physiol. 148:196-203 (1990)).

One source of donor c lls are established neural cell lin s. Many neuronal clones exist which have b en used extensively as model systems of development since they are electrically active with appropriate surface receptors,

- 5 specific neurotransmitters, synapse forming properties and the ability to differentiate morphologically and biochemically into normal neurons. Neural lines may express a tremendous amount of genetic information which corresponds to the genetic expression seen in CNS neurons. Such cells are
- 10 described in the following references: Kimhi, Y. et al.,

 Proc. Natl. Acad. Sci. USA 73:462-466 (1976); In: Excitable

 Cells in Tissue Culture, Nelson, P.G. et al., eds., Plenum

 Press, New York, 1977, pp. 173-245); Prasad, K.M. et al., In:

 Control of Proliferation of Animal Cells, Clarkson, B. et
- 15 <u>al.</u>, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1974, pp. 581-594); Puro, D.G. <u>et al.</u>, <u>Proc. Natl. Acad. Sci. USA 73</u>:3544-3548 (1976); Notter, M.F. <u>et al.</u>, <u>Devel. Brain Res. 26</u>:59-68 (1986); Schubert, D. <u>et al.</u>, <u>Proc. Natl. Acad. Sci. USA 67</u>:247-254 (1970); Kaplan, B.B. <u>et</u>
- 20 <u>al.</u>, In: <u>Basic and Clinical Aspects of Molecular Neurobiology</u>, Guffrida-Stella, A.M. <u>et al.</u>, eds., Milano Fondozione International Manarini, 1982)).

A major advantage of these cultured cells has been the potential to manipulate the environment, as well as the 25 cells themselves, in controlling the phenotype and genotype.

For example, human neuroblastoma cells from the IMR 32 cell line can survive and express cholinergic markers in primate brain nine months after transplantation (Gash, D.M. et al., Science 233:1420-22 (1986)). These cells are

- preferably treated to render them morphologically and biochemically differentiated <u>in vitro</u> and must be rendered permanently amitotic before implantation, which further aids in their survival (Gash <u>et al.</u>, <u>supra</u>; Gupta, M. <u>et al.</u>, <u>Dev. Brain Res.</u> 19:21-29 (1985)).
- Whereas untreated pheochromocytoma/neuroblastoma cells (PC12 cells) which grafted into the adult rat striatum showed no survival after two w eks in vivo (Hefti, F. et al.,

Brain Res. 348:283-288 (1985)), treatment in vitro with NGF to stimulate neural cell differentiation followed by exposure to antimitotic agents to inhibit cell proliferation, does not deleteriously affect catecholamine neurotransmitter expression nor viability and is of value for stimulating performance following transplant. Therefore, in one embodiment of the present invention, cell line cells are modulated in vitro with the appropriate growth or differentiation factor and with an amitotic agent before transplantation in order to promote cell survival and prevent expression of the malignant potential.

It will be apparent to one of ordinary skill in the art that examination of the neural cell surface of clonal cells in vitro using conventional methods will permit the 15 selection of appropriate cells for use according to the present invention. During normal development and differentiation, the neuronal cell surface undergoes significant changes which account for the migration, recognition and integration of neurons in the CNS. For example, when mouse 20 Cl300 clonal, neural cell lines are treated with antimitotic agents or growth modulators such as prostaglandin $\mathtt{E_1}$ and cyclic AMP, new low molecular weight cell surface glycoproteins are produced (Bottenstein, J.E., In: Functionally Differentiated Cell Lines, Sato, G.H., ed., Alan R. Liss, New 25 York, 1981). CNS surface gangliosides are induced which bind tetanus toxin (Notter, M.F., 1986, supra) while specific lectin binding glycoproteins appear which are similar to normal central nervous system glycoproteins. Additionally, receptors for neurotransmitters and neuropeptides on 30 neuroblastoma cells can be modified in a manner similar to cells found in the CNS (Costa, L.G. et al., Biochem. Pharmacol. 91:3407-3413 (1982).

Another important source of potential graft material are cells engineered by somatic cell hybridization, 35 a process which can immortalize single neurons. Somatic cell hybridization is a p werful c ll biologic tool used not only to generate cell lines with a variety of genotypes but to analyze the mechanisms r gulating the expression of various

WO 92/06702 PCT/US91/07443

phenotypes of differentiation. Fusing cells which differ in the expression of specific genes allows for the exploration of the mechanisms controlling gene expression while chromosome alterations occur at rates to generate genetically 5 different cell lines. Hybrid cells can be formed which retain the properties of differentiated cells. derived from fusion of sympathetic ganglia and neuroblastoma cells can synthesize dopamine (Greene, L.A. et al., Proc. Natl. Acad. Sci. USA 82:4923-4927 (1975) while brain cell 10 hybrids express choline acetyltransferase (Minna, J.D. et al., Genetics 79:373-383 (1975)). Therefore, embryonic precursors to dopaminergic neurons from the CNS can be fused with mitotic cells to incorporate both genomes into a single one that loses extra chromosomes over time and results in a 15 new hybrid line. It is within the skill of the art to produce such hybrid neural or paraneural cells without undue experimentation, screen them for the desired traits, such as dopamine secretion, and select those having the best

potential for transplantation. Another source of cells for transplantation 20 according to the present invention is the adrenal medulla. This neural crest-derived tissue has been involved in clinical trials (see Background) to treat PD. Adult monkey adrenal medulla can be cultured in vitro for at least about 25 three weeks as single cells (Notter, M.F. et al., Cell Tiss. Res. 244:69-76 (1986)). These cells respond to NGF by phenotypic alteration from the epithelioid, glandular morphology, to a neuronal morphology in which cells show extensive neuritic arborizations containing microtubular 30 arrays. This neuronal phenotype appears to be critical for long term survival of rat medullary cells in host CNS as well as their integration with host tissue (Stromberg, L. et al., supra). Transplanted adrenal medulla tissue can correct functional deficits resulting from nigrostriatal dopamine 35 d pletion in rats (see, for example, Freed et al., 1981, supra). This, however, is thought to be brought about by diffusion of dopamine from th transplant, a phenomenon that decreases thr e to six months after transplantation. NGF

treatment of the transplanted cells induces fiber outgrowth from the transplant into the host and induces a longer lasting behavioral recovery (at least a year). Indeed, without NGF treatment, few chromaffin cells transplanted 5 either to rat (Freed et al., supra) or rhesus monkey caudate nucleus (Morihisia, J.M. et al., Exp. Neurol. 84:643-653 (1984) using prior art techniques survive. Similarly, retinal pigment epithelial cells secrete dopamine and other factors and may be used for brain implants according to the 10 present invention (Li, L. et al., Exp. Eye Res. 47:771-785 (1988); Lui, G.M. et al., Proc. Int'l. Soc. Eye Res. 6:172 (1990); Li, L. et al., Inv. Ophthal. Vis. Sci. 31(Suppl):595 (1990, abstr. 2915-13); Sheedlo, H.J. et al., ibid., abstr. 2916-14; Fektorovich, E.G. et al., ibid. (abstr. 2917-15);

Cells transplanted into the mammalian brain according to the present invention have shown survival in the absence of added growth factors. However, an additional embodiment of the present invention is directed to transplantation of cells attached to a support matrix combined with the treatment, either <u>in vitro</u> prior to transplant, <u>in vivo</u> after transplant, or both, with the appropriate growth/differentiation factor

Human adrenal medullary cells can be maintained in vitro having the neuronal phenotype for at least nine weeks (Notter, M.F. et al., Schmitt Neurol. Sci. Symp., June 30, 1987, abstr.). NGF induces this conversion from the glandular state. Adrenal medullary cells co-cultured with C6 glioma cells exhibit extensive neuritic arborization and intimate contact with glioma cells. These astrocytic cells, treated with antimitotic agents to inhibit mitosis, are known to produce a growth factor similar to NGF which sustains sympathetic neurons in vitro (Barde, Y.A., Nature 274:818 (1978)). Grafted glial cells may play an important role in functional recovery of neurons and may be an important source of trophic factors (Doering, L.C. et al., J. Neurolog. Sci. 63:183-196 (1984); Gumple, J. et al., Neurosci. Lett. 37: 307-311 (1984)). Therefore, another embodiment of the

present inventi n involves co-culture of neural or paraneural cells with glial cells, their co-incubation with a support matrix, followed by implantation of the support matrix carrying both cell types.

- In additional embodiments of the present invention, 5 cells which are not of neural or paraneural origin, but which have been altered to produce a substance of neurological interest, are used. A preferred cell type is a human foreskin fibroblast which is easily obtained and cultured, 10 and survives upon transplantation into the rat brain using the methods of the present invention (see Example III). For use in the present invention, the cells are genetically altered, using methods known in the art, to express neuronal growth factors, neurotransmitters, neuropeptides, or enzymes 15 involved in brain metabolism. (See, for example, Gage, F.H. et al., Neuroscience 23:795-807 (1987); Rosenberg, M.B. et al., Science 242:1575-1578 (1988); Shimohama, S. et al., Mol. Brain Res. 5:271-278 (1989); which are hereby incorporated by
- reference). Standard reference works setting forth the general 20 principles of recombinant DNA technology and cell biology, which are hereby incorporated by reference, include Watson, J.D., et al., Molecular Biology of the Gene, Volumes I and II, Benjamin/Cummings Publishing Co., Inc., Menlo Park, CA 25 (1987); Darnell, J.E. et al., Molecular Cell Biology, Scientific American Books, Inc., New York, NY (1986); Lewin, B.M., Genes II, John Wiley & Sons, New York, NY (1985); Old,
- to Genetic Engineering, 2nd Ed., University of California 30 Press, Berkeley, CA (1981); Maniatis, T., et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (1982)); Sambrook, J. et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and Albers, B. et

R.W. et al., Principles of Gene Manipulation: An Introduction

35 al., Molecular Biology of th Cell, 2nd Ed., Garland Publishing, Inc., New York, NY (1989).

The recombinant DNA molecules useful for the methods of th pr s nt invention can b produced through any of a variety of means, such as, for example, DNA or RNA synthesis, or m re preferably, by application of recombinant DNA techniques. Techniques for synthesizing such molecules are disclosed by, for example, Wu, R., et al. (Prog. Nucl. Acid. Res. Molec. Biol. 21:101-141 (1978)). Procedures for constructing recombinant molecules are disclosed in detail by Sambrook et al., supra).

Typically, the gene or genes of interest are cloned from a library of expression vectors which has been prepared 10 by cloning DNA or, more preferably, cDNA (from a cell capable of expressing the gene) into an expression vector. library is then screened for members capable of expressing the gene product of interest, such as a neurotransmittersynthesizing enzyme, using antibody binding with an antibody 15 specific for the gene product. DNA, or more preferably cDNA, is extracted and purified from a cell which is capable of expressing the gene product of interest. The purified cDNA is fragmentized (by shearing, endonuclease digestion, etc.) to produce a pool of DNA or cDNA fragments. DNA or cDNA 20 fragments from this pool are then cloned into an expression vector in order to produce a library of expression vectors whose members each contain a unique cloned DNA or cDNA fragment.

An "expression vector" is a vector which (due to the presence of appropriate transcriptional and/or translational control sequences) is capable of expressing a DNA (or cDNA) molecule which has been cloned into the vector and of thereby producing a polypeptide or protein. Expression of the cloned sequences occurs when the expression vector is introduced into an appropriate host cell. An appropriate mammalian host cell would be any mammalian cell capable of expressing the cloned sequences. Procedures for preparing cDNA and for producing a genomic library are disclosed by Sambrook et al. (supra).

A DNA sequence encoding a product r products the expression of which is desired f r the present invention may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini

for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesiv ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.

5 Techniques for such manipulations are disclosed by Sambrook et al., supra, and are well known in the art.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and 10 translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene 15 expression. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the 20 DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the gene sequence coding for the protein may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-30 region naturally contiguous to the DNA sequence coding for the protein, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

Two DNA sequences (such as a promoter region sequence and a coding sequence) are said to be operably linked if the nature of the linkage between the two DNA

sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the
promoter region sequence to direct the transcription of the
coding sequence, or (3) interfere with the ability of the
5 coding sequence to be transcribed by the promoter region
sequence. A promoter region would be operably linked to a
DNA sequence if the promoter were capable of effecting
transcription of that DNA sequence. Thus, to express the
protein, transcriptional and translational signals recognized
10 by the host cell are necessary.

A promoter is a double-stranded DNA or RNA molecule which is capable of binding RNA polymerase and promoting the transcription of an "operably linked" nucleic acid sequence. As used herein, a "promoter sequence" is the sequence of the

- promoter which is found on that strand of the DNA or RNA which is transcribed by the RNA polymerase. A "promoter sequence complement" is a nucleic acid molecule whose sequence is the complement of a "promoter sequence." Hence, upon extension of a primer DNA or RNA adjacent to a single-
- 20 stranded "promoter sequence complement" or, of a "promoter sequence," a double-stranded molecule is created which will contain a functional promoter, if that extension proceeds towards the "promoter sequence" or the "promoter sequence complement." This functional promoter will direct the
- 25 transcription of a nucleic acid molecule which is operably linked to that strand of the double-stranded molecule which contains the "promoter sequence" (and not that strand of the molecule which contains the "promoter sequence complement").
- The promoter sequences useful for producing cells for the present invention may be either eukaryotic or viral. Suitable promoters are repressible, or, more preferably, constitutive. Useful eukaryotic promoters include the promoter of the mouse metallothionein I gene (Hamer, D., et al., J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of
- Herpes virus (McKnight, S., Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, C., et al., Nature (London) 290:304-310 (1981)). A preferred promoter, in particular for human fibroblasts, is the collagen promoter (Prockop, D.J. et al.,

N. Eng. J. Med. 301:13-23, 77-85 (1979); Eyre, D.R., Science 207:1315-1322 (1980); Martin, G.R. et al., Trends Bioch. Sci. 10:285-287 (1985); which references are hereby incorporated by reference).

Also intended within the scope of the present invention are cells attached to a support matrix, according to the invention, which are frozen and stored in a frozen state using methods well known in the art. Following thawing, the matrix-bound cells are implanted into a 10 recipient brain.

The cells useful in the methods of the present invention may be xenogeneic (= heterologous, i.e., derived from a species different from the recipient), allogeneic (= homologous, i.e., derived from a genetically different member of the same species as the recipient) or autologous, wherein the recipient also serves as the donor.

The number of cells needed to achieve the purposes of the present invention is variable depending on the size, age, weight of the subject, the nature of the underlying 20 disease, other concurrent therapies, and the like. This can be determined by one of skill in the art without undue experimentation. In an adult human, an effective number of cells attached to a support matrix are in the range of about 1 x 10³ to about 1 x 10⁷ cells, more preferably about 5 x 10³ to about 1 x 10⁶ cells. Alternatively, the effective amount of transplanted cells can be determined in terms of mass of cells added to a volume of beads, for example 40 mg of cell mass per ml of beads.

Materials of which the support matrix can be

30 comprised include those materials to which cells adhere
following in vitro incubation, and on which cells can grow,
and which can be implanted into a mammalian brain without
producing a toxic reaction, or an inflammatory or gliosis
reaction which would destroy the implanted cells or otherwise

35 interfere with their biological or therapeutic activity.
Such materials include, but are not limited to, glass and
other silicon oxides, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate,

polysulphone, polyvinyl alcohol, acryl nitrile polymers, polyacrylamid, polycarbonate, polypentene, nylon, amylas s, gelatin, collagen, natural and modified polysaccharides, including dextrans and celluloses (e.g. nitrocellulose), agar, and magnetite. Either resorbable or non-resorbable materials may be used.

The support matrix of the present invention is distinguished from that described by Aebischer and his colleagues (see above) in that, according to the present 10 invention, the cells are attached to the outer surface of the support; they are not encapsulated within a closed compartment, where their survival would be questionable given the exclusion capacity of the disclosed encapsulating supports. Furthermore, the support matrix of the present invention 15 presents no requirement that the material have particular permeability properties, such as the selective permeability of the Aebischer devices which allow low molecular weight substances to cross but exclude larger molecules (>50 kD).

The configuration of the support is preferably 20 spherical, as in a bead, but may be cylindrical, elliptical, a flat sheet or strip, a needle or pin shape, and the like. A preferred form of support matrix is a glass bead. preferred bead is a polystyrene bead. Bead sizes may range from about 10 μm to 1 cm in diameter, preferably from about 25 90 to about 150 μm . For a description of various microcarrier beads, see, for example, Fisher Biotech Source 87-88, Fisher Scientific Co., 1987, pp. 72-75; Sigma Cell Culture Catalog, Sigma Chemical Co., St. Louis, 1991, pp. 162-163; <u>Ventrex Product Catalog</u>, Ventrex Laboratories, 1989; 30 references are hereby incorporated by reference. The upper limit on the bead size is dictated by the bead's stimulation of undesired host reactions such as gliosis, which may interfere with the function of the transplanted cells or cause damage to the surrounding brain tissue. Such limita-35 tions are readily determinable by one of skill in the art.

To improve cell adhesion, survival and function, the solid matrix may optionally be coated on its external surface with factors known in the art to promote cell

adhesion, growth or survival. Such factors include cell adhesion molecules, extrac llular matrix, such as, for example, fibronectin, laminin, collagen, elastin, gycosaminoglycans, or proteoglycans (see: Albers, B. supra, pp. 802-5834) or growth factors, such as, for example, NGF. Alternatively, if the solid matrix to which the implanted cells are attached is constructed of porous material, the growth- or survival-promoting factor or factors may be incorporated into the matrix material, from which they would be slowly released after implantation in vivo.

In an alternate embodiment of the present invention, cells growing on resorbable matrices, such as, for example, collagen, can be implanted in sites of neurological interest other than the brain, in order to promote neuronal regrowth or recovery. For example, cells attached to the matrix of the invention may be implanted into the spinal cord, or placed in or adjacent to the optic nerve.

The methods of the present invention are useful for treating a number of human neurological disease. Parkinson's 20 Disease can be treated according to the present invention by implanting dopamine-producing cells in the recipient's striatum. Alzheimer's disease (AD) involves a deficit in cholinergic cells in the nucleus basalis. Thus, according to the invention, a subject having AD or at risk therefor may be 25 implanted with cells producing acetylcholine.

Huntington's disease involves a gross wasting of the head of the caudate nucleus and putamen, usually accompanied by moderate disease of the gyrus. A subject suffering from Huntington's disease can be treated by implanting cells producing the neurotransmitters gamma amino butyric acid (GABA), acetylcholine, or a mixture thereof. According to the present invention, the support matrix material to which such cells are attached is preferably implanted into the caudate and putamen.

Epilepsy is not truly a single disease but rather is a symptom produced by an underlying abnormality. One skilled in the art will appreciate that each epileptic subj ct will have damage or epileptic foci which are unique

for the individual. Such foci can be localized using a c mbination of diagnostic methods well-known in the art, including electroencephalography, computerized axial tomography and magnetic resonance imaging.

A patient suffering from epilepsy can be treated according to the present invention by implanting the support matrix material to which GABA-producing cells are attached into the affected site. Since blockers of glutamate receptors and NMDA receptors in the brain have been used to control experimental epilepsy, cells producing molecules which block excitatory amino acid pathways may be used according to the invention. Thus implantation of cells which have been modified as described herein to produce polyamines, such as spermidine, in larger than normal quantities may be useful for treating epilepsy.

The methods of the present invention are intended for use with any mammal which may experience the beneficial effects of the methods of the invention. Foremost among such mammals are humans, although the invention is not intended to 20 be so limited, and is also applicable to veterinary uses.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, 25 unless specified.

EXAMPLE I

Adrenal chromaffin cells from adult rats were prepared according to known methods (see: Inoue, M. et al., A. J. Physiol. 257 (Cell Physiol. 26):C906-912 (1989)).

- 30 After sacrifice by nembutal anesthesia followed by decapitation adrenal glands were removed. The medulla was freed of capsular and cortical material by careful microdissection. The tissue was cut into 2 or 3 pieces and incubated for 30 minutes with 0.2% collagenase in calcium-free balanced salt
- 35 solution containing 140 mM NaCl, 5 mM KCl, 5.2 mM MgCl $_2$, 5 mM HEPES, 10 mM D-glucose, at pH 7.4. During the enzyme

treatment, the preparation was shaken gently by bubbling through $99.9\%~O_2$. After dig stion, the tissue was washed three or four times with the above salt solution and then triturated gently in a pasteur pipet.

- The dissociated chromaffin cells were transferred to cell culture flasks containing serum free medium (Ventrex PC 1) and were cultured overnight at 37°C in a 5% CO₂ atmosphere. Under these conditions, the cells retain their viability for no more than a few days. Sterilized glass
- 10 beads (Ventrex, 90 micron) were added to the culture flask. The cells attached to the beads and essentially formed a monolayer on the beads. Within 24 hrs. of preparation in vitro, 1 to 5 μ l aliquots of the cell-carrying bead suspension were injected into the brains of anesthetized
- 15 adult rats. Later analysis, at times when the cells would not have survived in culture, the cells were found to be viable in vivo in the site surrounding the injection, (see Figure 1) as determined by immunocytochemical staining for tyrosine hydroxylase according to the Weiner procedure (see:
- 20 Kilpatrick, D.L. et al., J. Neurochem. 35:679 (1980);
 Hokfelt, R. et al., Handbook of Chemical Neuroanatomy,
 Elsevier Science Publishers, Amsterdam (1985)). The glass
 beads produced no necrotic damage above that typical of the
 injection itself.

25

EXAMPLE II

Adrenal medullae were removed from adult guinea pigs according to methods described in Example I and subjected to the procedure described in Example I. The cells on glass microbeads were injected into rat brain. The cells survived for a period of at least 21 days in a completely healthy state. No signs of immunological rejection were evident.

EXAMPLE III

Cultured human foreskin fibroblasts were attached 35 to glass microbeads as described above and injected into the rat brain. The cells were localized by immunofluorescence

using human IgG which selectively bound to the fibroblasts, followed by a fluorescein-conjugated goat anti-human IgG antibody. The implanted human cells survived for a period of at least 21 days in a completely healthy state. No signs of immunological rejection were evident.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and 20 as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation.

WHAT IS CLAIMED IS:

- A method for grafting a cell in the brain of a mammalian subject comprising attaching said cell to the outer surface of a support matrix <u>in vitro</u> and implanting said
 support matrix with said attached cell into said brain.
 - 2. The method of claim 1 wherein said support matrix is a microbead.
 - 3. The method of claim 2 wherein said microbead has a diameter from about 90 to about 150 μm .
- 4. The method of claim 1 wherein said support matrix is made of a material selected from the group consisting of silicone oxide, polystyrene, polypropylene, polyethylene, polycarbonate, polypentene, acrylonitrile polymer, nylon, natural polysaccharide, modified polysaccharide, amylase, collagen, natural cellulose, modified cellulose, agar and magnetite.
 - 5. The method of claim 4 wherein said support matrix is silicon oxide.
- 6. The method of claim 1 wherein said cell is of 20 neural or paraneural origin.
 - 7. The method of claim 6 wherein said cell is an adrenal chromaffin cell.
 - 8. The method of claim 1 wherein said cell is a retinal pigment epithelial cell.
- 9. The method of claim 1 wherein said cell is from a cell line cultured in vitro.
 - 10. The method of claim 9 wherein said cultured cell is a fibroblast.

- 11. The method of claim 9 wh rein said cultured cell has been genetically modified by transfection of genetic material encoding a protein or proteins rendering said genetically modified cell capable of producing a neurotrans5 mitter substance or a neuronal growth factor.
 - 12. A method for treating a neurological disease in a subject comprising grafting into the brain of said subject an effective number of cells capable of treating said disease according to the method of claim 1.
- 13. The method of claim 12 wherein said disease is selected from a group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury.

11



TGURE 1

U.S.	international Application No.	PC1/US91/0744
U.S.	SSIFICATI N OF SUBJECT MATTER III several planting	
1761	ng to international Patent Classification (IPC) or to both National Classification and IPC C1: 424/93,423,529,563,570,574; 435/240.23,240.24 5): A61K 37/00; C12N 5/00	
II FIEL	DS SEARCHED	
	Minimum Documentation Searched ?	
Classifica	tion System Classification Symbols	
u.s.	424/93,423,433,520,529,563,570,574;	
	435/74,176,177,179,180,240.1,240.2,240.23,240 604/891.1; 935/62.71	.24;
	Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched 8	
M	EDLINE, BIOSIS	
	MENTS CONSIDERED TO BE RELEVANT	
stegory •	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No.
••		
$\frac{X}{Y}$	US, A, 4,900,553 (Silver et al.) issued 13	,4,6,7.9.
1	February 1990, see the entire document.	12,13
		2.3.5
Y	US, A, 4,748,121 (Beaver et al) issued 31 Hay	
•	1988, see the entire document.	5
Y	Hernous in Enzymology, Volume Putte Thairman	1-13
	, "+ OCGITIET CULTUTE! A HOROGOROUS	1-13
1	Environment for Studies of Cellular	1
	Biochemistry*, pages 184-185, see the entire document.	·
Y	Science, Volume 242, issued 16 December 1988,	
	""" " " " " " " " " " " " " " " " " "	1-13
1	Demeded Disju: Reat Oretino Desce	
	Ut hur Expression! pages 1975-1977	
	of NGF Expression," pages 1575-1577, see entire	
	document.	
Y -	115, A, 4,892,538 (Aghischer et al.)	
Y -	115, A, 4,892,538 (Aghischer et al.)	1-13
(-	Cocament.	1-13
	US, A, 4,892,538 (Aebischer et al.) 09 January 1990, see entire document.	
Special c	LIS, A, 4,892,538 (Aebischer et al.) 09 January 1990, see entire document. Response of cited documents: 10 Artificial document published after the entire defining the general state of the entire document of property data and not a confidence of the entire defining the general state of the entire data.	international filing date
Special of documents of the control	Jis, A, 4,892,538 (Aebischer et al.) 09 January 1990, see entire document. alegories of cited documents: 10 ent defining the general state of the art which is not ered to be of particular relevance document but outletshed on a refer the comment but outletshed a refer the comment but ou	international filing date with the application but or theory underlying the
Special c	IIS, A, 4,892,538 (Aebischer et al.) 09 January 1990, see entire document. ategories of cited documents: 10 ent defining the general state of the art which is not ered to be of particular relevance document but published on or after the international late my definition may them doubte an area to international late. """ later document published after the or prooring document but published on or after the international late. """ later document published after the or prooring the principle my sentence of sarticular relevance cannot be considered novel or co	i international filing date with the application but or theory underlying the
Special c " docum consid " earlier filing c " docum which citaber	LIS, A, 4,892,538 (Aebischer et al.) January 1990, see entire document. ategories of cited documents: 10 ent defining the general state of the art which is not leved to be of particular relevance document but published on or after the international late ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another of comment of particular relevance cannot be considered novel or cited to establish the publication date of another or or other special reason (as assection). "Y" document of particular relevance cannot be considered novel or cited to establish the publication date of another or or other special reason (as assection). "Y" document of particular relevance cannot be considered novel or cited to establish the publication date of another or confidence.	i international filing date with the application but or theory underlying the the claimed invention annot be considered to
Special of documents of the service	January 1990, see entire document. 21	international filing date with the application but or theory underlying the : the claimed invention annot be considered to : the claimed invention inventive step when the
Special c a docum consid arrier filing c docum which citaber docum	IIS, A, 4,892,538 (Aebischer et al.) January 1990, see entire document. "T" later document oublished after the ent defining the general state of the art which is not leved to be of particular relevance document but published on or after the international ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another of their special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent sublished prior to the international fixing date but an entire the entire document oublished after the or priority date and not in conflict cited to understand the principle inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot be considered to involve an inventor of particular relevance cannot of the particular relevance cannot be considered to involve an inventor	i international filing date with the application but or theory underlying the : the claimed invention annot be considered to ; the claimed invention inventive step when the more other such docureus to a person skilled
Special c A docum consid arrier filing docum which crimes docum other docum later th	IIS, A, 4,892,538 (Aebischer et al.) Istegories of cited documents: 10 Interest of cited document oublished after the or proving date and not in conflict cited to understand the principle invention of the cited to understand the principle invention of the cited to establish the publication date of another or involve an inventive step in or other apocal reason (as specified) Interest document of sarticular relevance cannot be considered novel or confidence inventive and document is combined with one of the art. In the stricting date claimed	i international filing date with the application but or theory underlying the : the claimed invention annot be considered to : the claimed invention inventive step when the more other such docureus to a person skilled
Special of a document of the control	LIS, A, 4,892,538 (Aebischer et al.) January 1990, see entire document. "T" later document oublished after the property designing the general state of the art which is not ered to be of particular relevance document but published on or after the international late ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another or or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international fiking date but an the priority date claimed CATION "T" later document oublished after the or priority date and not in conflict cited to understand the principle myenition. "T" later document oublished after the or priority date and not in conflict cited to understand the principle myenition. "X" document of particular relevance cannot be considered to involve an document is combined with one or means. Such combination being obtained prior to the international fiking date but an the gri. "4" document member of the same set	i international filing date with the application but or theory underlying the : the claimed invention annot be considered to : the claimed invention inventive step when the more other such documous to a person skilled ent family
Special of A document of the A	LIS, A, 4,892,538 (Aebischer et al.) Stegories of cited documents: 10 Ment defining the general state of the art which is not sered to be of particular relevance document but published on or after the international state of the stablish the publication date of another is cited to establish the publication date of another is considered navel or cannot be considered to involve an document is commended with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or not relevance cannot be considered to involve an document is commend with one or involve and document is co	i international filing date with the application but or theory underlying the : the claimed invention annot be considered to : the claimed invention inventive step when the more other such documous to a person skilled ent family
Special of a document of the A	LIS, A, 4,892,538 (Aebischer et al.) January 1990, see entire document. attegories of cited documents: 10 ent defining the general state of the art which is not leved to be of particular relevance document but published on or after the international late ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another or or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent sublished prior to the international fixing date but the structure of the international fixing date but the structure of the international Search Date of Making of this international Search Date of Making of this international Search	i international filing date with the application but or theory underlying the : the claimed invention annot be considered to : the claimed invention inventive step when the more other such docurrous to a person skilled ent family



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 92/06702 (11) Internati nal Publication Number: (51) International Patent Classification 5: 30 April 1992 (30.04.92) A1 (43) Internati nal Publication Date: A61K 37/00, C12N 5/00 (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent) PCT/US91/07443 (21) International Application Number: pean patent), DK (European patent). ES (European patent), FR (European patent), GB (European patent), GR 9 October 1991 (09.10.91) (22) International Filing Date: (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European pa-(30) Priority data: 19 October 1990 (19.10.90) US 599,802 (71) Applicant: NEW YORK UNIVERSITY [US/US]; 550 **Published** With international search report. First Avenue, New York, NY 10016 (US). (72) Inventor: CHERKSEY, Bruce, D.; 608 Garden Street, Hoboken, NJ 07030 (US). (74) Agent: BROWDY, Roger, L.; Browdy and Neimark, 419 Seventh Street, N.W., Suite 300, Washington, DC 20004 (US).

(54) Title: A METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USES THEREFOR

(57) Abstract

A method for grafting a cell in the brain of a mammalian subject is accomplished by attaching the cell to a support matrix so that the cell attaches to the matrix outer surface, and implanting the support matrix with the attached cell into the brain. Preferred support matrices are glass or plastic microbeads having a diameter from about 90 to about 125 μm. The method employs cells of different types, preferably cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury.

^{* (}Referred to in PCT Gazette No. 12/1992, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria				
AU	Austrolia	. RS	Spain	MG	Madagascar
88	:- <u>_</u>	FI	Finland	ML	Muli
_	Barbulos	FR	France		
88	Acigium	CA	Guhon	MN	Mongolia
8p	Burking Faco	G8	United Kingdom	MR	Mauritania
B C	Bulgaria	GN		MW	Malawi
E.J	Bunin		Guinca	NL.	Netherlands
BR	Brazit	GR	Groece	NO	Norway
CA		HU	Hungary	PL	Polund
_	Conada	IT	italy	RO	Romania
CF	Central African Republic	JP.	Japan	_	
œ	Congo	KP	Democratic People's Republic	SD	Sudan
CH	Switzerland		of Korea	SE	Swoden
CI	Côte d'Ivoire	~-		SN	Schegal
СМ	Cameroon	KR	Republic of Korca	SU+	Soviet Union
CS	Czechoslovakia	LI	Licehtenstein	TD	Chad
DE.		LK	Sri Lenka	TC	Togo
_	Germany :	ш	Luxembourg	US	•
DK	Dunmark	840	Manage	Ug	United States of America

⁺ Any designati n f "SU" has effect in the Russian Federati n. It is not yet known whether any such designati n has effect in other States of the former Soviet Union.

A METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USES THEREFOR

BACKGROUND OF THE INVENTION

5 Field of the Invention

The invention in the field of neuroscience and medicine relates to methods for implantation or transplantation of cells into the mammalian brain, useful in treating neurological disorders.

10 Description of the Background Art

Grafting of neural cells and neuron-like cells directly into the brain may be a practical approach to promote recovery from debilitating diseases of the nervous system such as Parkinson's disease (PD), Huntington's disease

- 15 (HD), Alzheimer's disease (AD), epilepsy, and familial dysautonomia, as well as injury or trauma to the nervous system. The characterization of factors which influence neurotransmitter phenotypic expression in cells placed into the brain may lead to a better understanding of processes
- 20 involved in normal specification in the nervous system and indicate means by which birth defects resulting from aberrant phenotypic expression can be therapeutically prevented or corrected.
- Neurons or neuronal-like cells can be grafted into 25 the central nervous system (CNS), in particular, into the brain, either as solid tissue blocks or as dispersed cells. However, to date, a number of problems of both a technical and ethical nature have plagued the development of clinically feasible grafting procedures.
- Parkinson's disease (PD) results from a selective loss of dopaminergic nigrostriatal neurons, resulting in a loss of input from the substantia nigra to the striatum. Solid grafts of tissues potentially capabl of producing dopamine, such as adult adrenal medulla and embryonic substantia nigra
- 35 (SN), have been used extensively for experimental grafting in rats and primates treated with 6-hydroxydopamine (6-OHDA) to

destroy dopaminergic cells (Dunnett, S.B. et al., Brain Res. 215: 147-161 (1981); ibid. 229:457-470 (1981); Morisha, J.M. et al., Exp. Neurol. 84:643-654 (1984); Perlow, M.J. et al., Science 204:643-647 (1979)). Grafts of embryonic SN have also been used as therapy for primates lesioned with the neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), which produces a PD-like disease (Redmond, D.E. et al., Lancet 8490:1125-27 (1986)).

Stenevi et al. (Brain Res. 114:1-20 (1976), in investigating the optimal conditions for neural graft survival, found that the best results were obtained when (a) fetal CNS neurons were used, and (b) the transplanted cells were placed next to a rich vascular supply. In fact, a review of the literature reveals that tissue from almost every area of the fetal brain can be successfully transplanted if care is taken with procedural details (see, for example, Olson, L. A. et al., In: Neural Transplants:

Development and Function, Sladek, J.R. et al., eds, Plenum Press, New York, 1984, pp. 125-165).

Embryonic tissue provides an excellent source of cells which will differentiate in a foreign environment and become integrated with the host tissue. For example, grafts of embryonic SN into 6-OHDA treated rats have been shown to produce dopamine, to reduce apomorphine- or amphetamine
25 induced rotation, to alleviate sensory deficits and to make synapses in the host striatum (Dunnett et al., Morisha et

synapses in the host striatum (Dunnett et al., Morisha et al., Perlow et al., supra). Grafted neurons are also spontaneously active, thus mimicking normal adult SN neurons (Wuerthele, S.M. et al., In: Catecholamines, Part B, (E.

30 Usdin et al., eds.), A.R. Liss, Inc., New York, pp. 333-341).

In contrast to successful grafting of fetal neural tissue, mature CNS neurons have never been found to survive in transplants (Stenevi, U. et al., Brain Res. 114:1-20 (1976)). The reason f tal CNS neurons survive grafting procedures while adult neur ns do not, while uncertain, is probably related to several factors. First, fetal neurons are less affected by low oxygen levels than mature neurons

(Jilek, L., In: <u>Developmental Neurobiology</u>, Himwich, W.A., ed., C.C. Thomas Publisher, Springfield, IL, 1970, pp. 331-369), and grafting procedures necessarily involve periods of anoxia until an adequate blood supply to the transplant is established. Secondly, fetal neurons seem to survive best when they are taken during a rapid growth phase and before connections are established with target tissues (Boer, G.J. et al., Neuroscience 15:1087-1109, (1985)). Also, fetal tissue may be especially responsive to growth (or "survival") factors which are known to be present in the milieu of the damaged host brain (Nieto-Sampedro, M. et al., <u>Science</u> 217:860-861 (1982); <u>Proc. Natl. Acad. Sci. USA</u> 81:6250-6254 (1984)).

However, despite the promise of fetal tissue and 15 cell transplants, the art has turned to alternate sources of donor tissues for transplantation because of the ethical, moral, and legal problems attendant to utilizing fetal tissue in human medicine. These sources include neural and paraneural cells from organ donors and cultured cell lines.

20 (See, for example: Gash, D.M. et al., In: Neural Grafting in the Mammalian CNS, Bjorklund, A. et al., eds, Elsevier, Amsterdam, 1985, pp. 595-603; Gash, D.M. et al., Science 233:1420-22 (1986)).

Although early clinical experiments using the
25 grafting approach did not result in long-lasting effects, an
initial report of one study appeared more promising (Madrazo
et al., Soc. Neurosci. Abstr. 12:563 (1986); for an overvi w,
see: Lieberman, A. et al., Adv. Tech. Stand. Neurosurg.
17:65-76 (1990), which is hereby incorporated by reference).

- 30 Several additional observations suggest that grafting adrenal cells should be a viable approach. Adrenal medullary cells are derived from the neural crest and, like sympathetic neurons, grow processes in vivo or in vitro in response to nerve growth factor (NGF) (Unsicker, K. et al., Proc. Natl.
- 35 Acad. Sci. USA 75:3498-3502 (1978)). Solid grafts of adrenal medulla from y ung rats can survive in the brain of 6-OHDA treat d rats for at least 5 months, produce dopamine and reduce apomorphine induced rotation (Dunnett et al., supra;

Freed, W.J. et al., Ann. Neurol. 8:510-519 (1980); Fr ed, W.J. et al. Science 222:937-939 (1983)). These obs rvations suggest that given the appropriate environment, adrenal medullary cells have the potential for growing catecholamine-5 synthesizing fibers into brain tissue.

The potential for neuronal differentiation of chromaffin cells is even better elucidated by grafts of dissociated adrenal chromaffin cells which grow processes when injected into rat striatum. Cultured adrenal medullary 10 cells also differentiate into neuronal-like cells with processes when cultured in the presence of NGF (Unsicker, supra). This remarkable plasticity of adrenal cells is observed not only in morphology, but also in neurotransmitter phenotypic expression. An array of neuropeptides including 15 vasoactive intestinal peptide, as well as the monoamine, serotonin, are co-localized with catecholamines in adrenal medullary cells (Schultzberg, M. Neurosci. 3:1169-1186 (1978); Lundberg, J.M. Proc. Natl. Acad. Sci. USA 76:4079-4082 (1979)). Expression of these various phenotypes can be 20 modulated by extrinsic signals. For example, enkephalin and VIP expression are increased following denervation of the adrenal in vivo, by treatment of animals with nicotinic blockers or after maintaining adrenal cells in vitro (Tischler, A.S. <u>Life Sci.</u> 37:1881-1886 (1985)). 25 observations taken together with those of other studies demonstrating that neurons derived from the neural crest can switch phenotype during normal development (Bohn, M.C. et al., Devel. Biol. 82:1-10 (1981); Jonakait, G.M. et al. Devel. Biol. 88:288-296 (1981)) or following experimental 30 manipulation of the micromilieu (LeDouarin, N.M. Science 231: 1515-1522 (1986)) suggest that, in the future, it may be possible to control the neurotransmitter phenotype expressed

by grafted cells either before and/or after grafting.

An additional advantage of grafting dissociated

35 cells compared to blocks f tissue is that the c lls can be precultured with various substances such as growth factors prior to grafting or they can be co-grafted with other cells or substances which pr mote specific parameters of differen-

tiation. Furthermor, glial cells may have specific regional effects and produce neuronal growth factors (Barbin, G. et al., Devel. Neurosci. 7:296-307 (1985); Schurch-Rathgeb, Y. et al., Nature 273:308-309 (1978); Unsicker, K. et al. Proc.

Natl. Acad. Sci. USA 81:2242-2246 (1984); Whitaker-Azmitia, P.M. et al., Brain Res. 497:80-85 (1989)). This suggests that co-transplanting cells providing the desired neurotransmitters along with specific types of glia which produce glial-derived factors, may promote neuronal growth and the desired differentiation of grafted cells.

Thus, the feasibility of the transplant approach has been established experimentally. However, this approach is severely limited by the need for the use of fetal tissue, which is of limited availability and of great political consequence. In essence, transplantation of human fetal

- 15 consequence. In essence, transplantation of human fetal tissue from aborted pregnancies has been prohibited in th United States. It would thus be of great benefit if simple, routine and safe methods for the successful transplantation of adult tissue into the brain were available for the
- 20 treatment of debilitating neurological disease.

 Aebischer and his colleagues have successfully implanted selectively permeable biocompatible polymer capsules into the brain which encapsulated fragments of neural tissue which survived in this environment (Aebischer,
- 25 P. et al., Brain Res. 448:364-368 (1988); Winn, S.R. et al.,

 J. Biomed Mater Res. 23:31-44 (1989). The polymer capsules
 consisted of polyvinyl chloride acrylic copolymer XM-50.

 Such permselective material completely prevented the invasion
 of the encapsulated tissue by host cells, and presumably
- antibodies and viruses as well, based on the permeability of the membrane. When dopamine-releasing polymer rods were encapsulated into such a permselective polymer and implanted into denervated striatum in rats, alleviation of the experimentally induced Parkinson disease symptoms was
- 35 achieved (Winn S.R. et al., Exp. Neurol. 105:244-50 (1989). Furtherm re, US Patent 4,892,538 (Aebischer et al., issued 1/9/90) discloses a cell culture devic for implantation in a subject for delivery of a neur transmitter comprising

secr ting c lls within a semipermeable membrane which permits diffusion of the neurotransmitter while excluding viruses, antibodies and other detrimental agents present in the external environment. The semipermeable membrane is of an 5 acrylic copolymer, polyvinylidene fluoride, polyurethane, polyalginate, cellulose acetal, polysulphone, polyvinyl alcohol, polyacrylonitrile, or their derivatives or mixtures and permits diffusion of solute of up to 50 kD molecular weight. This device is said to be useful in treatment of 10 neurotransmitter-deficient conditions, such as Parkinson's disease, by sustained, local delivery of neurotransmitters, precursors, agonists, fragments, etc., to a target area, especially the brain. The device may be made retrievable so that the contents may be renewed or supplemented, and the 15 cells are protected against immunological response and viral infection.

SUMMARY OF THE INVENTION

The inventors have made the unexpected discovery that by first culturing cells in vitro on a support matrix, 20 such as 90 μm diameter glass beads, such cells including mature CNS neurons or cultured cells, can be successfully transplanted into the mammalian brain. The beads, to which the cells adhere, are stereotaxically injected into the recipient's brain. Cells so injected retain their viability 25 and are thus effectively transplanted. They show prolonged survival and viability in vivo, even when transplanted across species barriers.

It is an objective of the present invention to overcome the aforementioned deficiencies in the prior work.

- The present invention provides a method for grafting a cell in the brain of a mammalian subject comprising culturing the cell with a support matrix so that the cell attaches to said matrix, and implanting the support matrix with the attach d cell into the brain.
- The method includes support matrices made of glass and other silicon oxides, polystyren , polypropylene,

p lyethylene, polyacrylamide, polycarbonate, polypentene, acrylonitrile polymers, nylon, amylases, gelatin, collagen, natural and modified polysaccharides, including dextrans and celluloses (e.g. nitrocellulose), agar, and magnetite.

5 Preferred support matrices are beads, in particular microbeads having a diameter from about 90 to about 150 μm .

The method of the present invention may employ cells of many different types, preferably either cells of neural or paraneural origin, such as adrenal chromaffin

- 10 cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following transfection with DNA encoding a neuropeptide or an enzyme or set of enzymes which results in production of neurotransmitter, or a neuronal growth factor.
- The present invention includes a method for treating a neurological disease in a subject which comprises grafting an effective number of cells capable of treating the disease according to the above methods. Diseases which can be treated according to the present invention include, but
- 20 are not limited to, Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, familial dysautonomia, and traumatic brain injury.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photomicrograph of a section of the

25 brain of a rat implanted with adult adrenomedullary cells on
a glass microbead. The section was fixed an stained
histochemically for tyrosine hydroxylase (TH) using horse
radish peroxidase. The darkly stained areas indicate cells
containing TH. The pattern of staining shows a needle tract

30 entering the section on the right side. The large circular
stained area in the center represents the bulk of the
implanted cells. Te injected cells form a "gland-like"
pattern, with some extending back into the needle tract.
(Thickness: 20 microns; magnification: 100x)

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is based on the unexpected discovery by the inventors that adult cells or cultured cells which cannot normally be transplanted into a mammalian brain and survive, can be made to survive by first attaching them to a support matrix.

A number of different cell types are useful for the present invention. Typically, a cell will be selected based on its ability to provide a missing substance to the

- 10 recipient brain. Missing substances can be neurotransmitters or other neurally-active molecules, the absence of which results in neurological disease or dysfunction. It is important that the transplanted cell not grow as a tumor once it is inserted into the recipient.
- The references cited below are all incorporated by reference herein, whether specifically incorporated or not.

By the term "neural or paraneural origin" is intended a cell which is derived from the embryonic neural crest. A preferred example of a cell of paraneural origin is

- 20 a adrenal medullary chromaffin cell. The precursor cells to the mammalian adrenal medulla are of neural crest origin and possess the potential to develop along either neuronal or endocrine lines of differentiation (Bohn, M.C. et al., 1981, supra, Devel. Biol. 89:299-308 (1982); Unsicker, K., Develop.
- Biol. 108:259-268 (1985)). Chromaffin cells from the rat, monkey, and human adrenal medulla, when removed from adrenal cortical influences and exposed to nerve growth factor (NGF), change from an endocrine to a neuronal phenotype (Notter, M.F. et al., Cell Tiss. Res. 244:69-70 (1986); Stromberg, I.
- 30 et al., Exp. Brain Res. 60:335-349 (1985); Unsicker, K. et al., 1978, supra). When co-grafted with cerebral cortical or hippocampal tissue into the anterior chamber of the rat eye, adrenal chromaffin cells form nerve fibers which innervate the adjacent co-grafted brain tissue (Olson, L. A. et al.,
- 35 Exp. Neurol. 70414-426 (1980)). Another paran ural cell type is a retinal pigment epithelium cell (Song, M-K et al., J. Cell. Physiol. 148:196-203 (1990)).

One source of don r cells are established neural c ll lines. Many neuronal clones exist which have been used extensively as model systems of development since they are electrically active with appropriate surface receptors,

- 5 specific neurotransmitters, synapse forming properties and the ability to differentiate morphologically and biochemically into normal neurons. Neural lines may express a tremendous amount of genetic information which corresponds to the genetic expression seen in CNS neurons. Such cells are
- 10 described in the following references: Kimhi, Y. et al.,

 Proc. Natl. Acad. Sci. USA 73:462-466 (1976); In: Excitable

 Cells in Tissue Culture, Nelson, P.G. et al., eds., Plenum

 Press, New York, 1977, pp. 173-245); Prasad, K.M. et al., In:

 Control of Proliferation of Animal Cells, Clarkson, B. et
- 15 al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1974, pp. 581-594); Puro, D.G. et al., Proc. Natl. Acad. Sci. USA 73:3544-3548 (1976); Notter, M.F. et al., Devel. Brain Res. 26:59-68 (1986); Schubert, D. et al., Proc. Natl. Acad. Sci. USA 67:247-254 (1970); Kaplan, B.B. et
- 20 al., In: <u>Basic and Clinical Aspects of Molecular Neurobiology</u>, Guffrida-Stella, A.M. <u>et al.</u>, eds., Milano Fondozione International Manarini, 1982)).

A major advantage of these cultured cells has been the potential to manipulate the environment, as well as the 25 cells themselves, in controlling the phenotype and genotype.

For example, human neuroblastoma cells from the IMR 32 cell line can survive and express cholinergic markers in primate brain nine months after transplantation (Gash, D.M. et al., Science 233:1420-22 (1986)). These cells are

- opreferably treated to render them morphologically and biochemically differentiated in vitro and must be rendered permanently amitotic before implantation, which further aids in their survival (Gash et al., supra; Gupta, M. et al., Dev. Brain Res. 19:21-29 (1985)).
- Whereas untreated pheochromocytoma/neuroblastoma cells (PC12 cells) which grafted into the adult rat striatum showed no survival after two we ks in vivo (Hefti, F. et al.,

Brain Res. 348:283-288 (1985)), treatment in vitro with NGF t stimulate neural cell differentiation followed by exposure to antimitotic agents to inhibit cell proliferation, does not deleteriously affect catecholamine neurotransmitter expression nor viability and is of value for stimulating performance following transplant. Therefore, in one embodiment of the present invention, cell line cells are modulated in vitro with the appropriate growth or differentiation factor and with an amitotic agent before transplantation in order to promote cell survival and prevent expression of the malignant potential.

It will be apparent to one of ordinary skill in the art that examination of the neural cell surface of clonal cells in vitro using conventional methods will permit the 15 selection of appropriate cells for use according to the present invention. During normal development and differentiation, the neuronal cell surface undergoes significant changes which account for the migration, recognition and integration of neurons in the CNS. For example, when mouse 20 C1300 clonal, neural cell lines are treated with antimitotic agents or growth modulators such as prostaglandin ${\mathtt E}_1$ and cyclic AMP, new low molecular weight cell surface glycoproteins are produced (Bottenstein, J.E., In: Functionally Differentiated Cell Lines, Sato, G.H., ed., Alan R. Liss, New 25 York, 1981). CNS surface gangliosides are induced which bind tetanus toxin (Notter, M.F., 1986, supra) while specific lectin binding glycoproteins appear which are similar to normal central nervous system glycoproteins. Additionally, receptors for neurotransmitters and neuropeptides on 30 neuroblastoma cells can be modified in a manner similar to cells found in the CNS (Costa, L.G. et al., Biochem. Pharmacol. 91:3407-3413 (1982).

Another important source of potential graft material are cells engineered by somatic cell hybridization, 35 a process which can immortaliz singl neur ns. Somatic cell hybridization is a powerful cell biologic t ol used not only to generate cell lines with a variety of genotypes but to analyze the mechanisms regulating the expression of various

.41

phenotypes of differentiation. Fusing cells which differ in the expression of specific genes allows for the exploration of the mechanisms controlling gene expression while chromosome alterations occur at rates to generate genetically 5 different cell lines. Hybrid cells can be formed which retain the properties of differentiated cells. derived from fusion of sympathetic ganglia and neuroblastoma cells can synthesize dopamine (Greene, L.A. et al., Proc. Natl. Acad. Sci. USA 82:4923-4927 (1975) while brain cell 10 hybrids express choline acetyltransferase (Minna, J.D. et al., Genetics 79:373-383 (1975)). Therefore, embryonic precursors to dopaminergic neurons from the CNS can be fused with mitotic cells to incorporate both genomes into a single one that loses extra chromosomes over time and results in a 15 new hybrid line. It is within the skill of the art to-8 produce such hybrid neural or paraneural cells without undue experimentation, screen them for the desired traits, such as

Another source of cells for transplantation according to the present invention is the adrenal medulla. This neural crest-derived tissue has been involved in clinical trials (see Background) to treat PD. Adult monkey adrenal medulla can be cultured in vitro for at least about three weeks as single cells (Notter, M.F. et al., Cell Tiss. Res. 244:69-76 (1986)). These cells respond to NGF by phenotypic alteration from the epithelioid, glandular morphology, to a neuronal morphology in which cells show extensive neuritic arborizations containing microtubular

dopamine secretion, and select those having the best

potential for transplantation.

30 arrays. This neuronal phenotype appears to be critical for long term survival of rat medullary cells in host CNS as well as their integration with host tissue (Stromberg, L. et al., supra). Transplanted adrenal medulla tissue can correct functional deficits resulting from nigrostriatal dopamine

35 depleti n in rats (see, f r example, Fr ed et al., 1981, supra). This, however, is thought to b brought about by diffusion of dopamine from the transplant, a phenomenon that decreases three to six months after transplantation. NGF

treatment of th transplanted cells induces fiber outgrowth from the transplant into th host and induces a long r lasting behavioral recovery (at least a year). Indeed, without NGF treatment, few chromaffin cells transplanted 5 either to rat (Freed et al., supra) or rhesus monkey caudate nucleus (Morihisia, J.M. et al., Exp. Neurol. 84:643-653 (1984) using prior art techniques survive. Similarly, retinal pigment epithelial cells secrete dopamine and other factors and may be used for brain implants according to the 10 present invention (Li, L. et al., Exp. Eye Res. 47:771-785 (1988); Lui, G.M. et al., Proc. Int'l. Soc. Eye Res. 6:172 (1990); Li, L. et al., Inv. Ophthal. Vis. Sci. 31(Suppl):595 (1990, abstr. 2915-13); Sheedlo, H.J. et al., ibid., abstr. 2916-14; Fektorovich, E.G. et al., ibid. (abstr. 2917-15);

Cells transplanted into the mammalian brain according to the present invention have shown survival in the absence of added growth factors. However, an additional embodiment of the present invention is directed to transplantation of cells attached to a support matrix combined with the treatment, either in vitro prior to transplant, in vivo after transplant, or both, with the appropriate growth/differentiation factor.

Human adrenal medullary cells can be maintained in vitro having the neuronal phenotype for at least nine weeks (Notter, M.F. et al., Schmitt Neurol. Sci. Symp., June 30, 1987, abstr.). NGF induces this conversion from the glandular state. Adrenal medullary cells co-cultured with C6 glioma cells exhibit extensive neuritic arborization and intimate contact with glioma cells. These astrocytic cells, treated with antimitotic agents to inhibit mitosis, are known to produce a growth factor similar to NGF which sustains sympathetic neurons in vitro (Barde, Y.A., Nature 274:818 (1978)). Grafted glial cells may play an important role in functional recovery of neurons and may be an important source of trophic factors (Doering, L.C. et al., J. Neurolog. Sci. 63:183-196 (1984); Gumple, J. et al., Neurosci. Lett. 37: 307-311 (1984)). Therefore, an ther embodiment of the

present invention involves co-culture of neural or paran ural cells with glial cells, th ir co-incubation with a support matrix, followed by implantation of the support matrix carrying both cell types.

- In additional embodiments of the present invention, cells which are not of neural or paraneural origin, but which have been altered to produce a substance of neurological interest, are used. A preferred cell type is a human foreskin fibroblast which is easily obtained and cultured,
- 10 and survives upon transplantation into the rat brain using the methods of the present invention (see Example III). For use in the present invention, the cells are genetically altered, using methods known in the art, to express neuronal growth factors, neurotransmitters, neuropeptides, or enzymes
- 15 involved in brain metabolism. (See, for example, Gage, F.H. et al., Neuroscience 23:795-807 (1987); Rosenberg, M.B. et al., Science 242:1575-1578 (1988); Shimohama, S. et al., Mol. Brain Res. 5:271-278 (1989); which are hereby incorporated by reference).
- Standard reference works setting forth the general principles of recombinant DNA technology and cell biology, which are hereby incorporated by reference, include Watson, J.D., et al., Molecular Biology of the Gene, Volumes I and II, Benjamin/Cummings Publishing Co., Inc., Menlo Park, CA
- 25 (1987); Darnell, J.E. et al., Molecular Cell Biology, Scientific American Books, Inc., New York, NY (1986); Lewin, B.M., Genes II, John Wiley & Sons, New York, NY (1985); Old, R.W. et al., Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2nd Ed., University of California
- Oloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (1982)); Sambrook, J. et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and Albers, B. et
- 35 al., Molecular Biology of the Cell, 2nd Ed., Garland Publishing, Inc., New York, NY (1989).

The recombinant DNA molecules useful for th methods of the pr sent invention can be produced through any

of a variety of means, such as, for exampl , DNA or RNA synthesis, or more preferably, by application of recombinant DNA techniques. Techniques for synthesizing such molecules are disclosed by, for example, Wu, R., et al. (Prog. Nucl. Acid. Res. Molec. Biol. 21:101-141 (1978)). Procedures for constructing recombinant molecules are disclosed in detail by Sambrook et al., supra).

Typically, the gene or genes of interest are cloned from a library of expression vectors which has been prepared 10 by cloning DNA or, more preferably, cDNA (from a cell capable of expressing the gene) into an expression vector. The library is then screened for members capable of expressing the gene product of interest, such as a neurotransmittersynthesizing enzyme, using antibody binding with an antibody 15 specific for the gene product. DNA, or more preferably cDNA, is extracted and purified from a cell which is capable of expressing the gene product of interest. The purified cDNA is fragmentized (by shearing, endonuclease digestion, etc.) to produce a pool of DNA or cDNA fragments. DNA or cDNA 20 fragments from this pool are then cloned into an expression vector in order to produce a library of expression vectors whose members each contain a unique cloned DNA or cDNA fragment.

An "expression vector" is a vector which (due to 25 the presence of appropriate transcriptional and/or translational control sequences) is capable of expressing a DNA (or cDNA) molecule which has been cloned into the vector and of thereby producing a polypeptide or protein. Expression of the cloned sequences occurs when the expression vector is introduced into an appropriate host cell. An appropriate mammalian host cell would be any mammalian cell capable of expressing the cloned sequences. Procedures for preparing cDNA and for producing a genomic library are disclosed by Sambrook et al. (supra).

A DNA sequence encoding a product or products the expression of which is desired for the present invention may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini

for ligation, restriction enzyme digestion to provide appropriate termini, filling in of coh sive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.

5 Techniques for such manipulations are disclosed by Sambrook et al., supra, and are well known in the art.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and

- 10 translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene
- 15 expression. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the
- 20 DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.
- If desired, the non-coding region 3' to the gene sequence coding for the protein may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-
- 30 region naturally contiguous to the DNA sequence coding for the protein, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be sub-35 stituted.

Two DNA sequences (such as a promoter region sequence and a coding sequence) are said to be operably linked if the nature of the linkage betw en the two DNA

sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the
promoter region sequence to direct the transcription of the
coding sequence, or (3) interfere with the ability of the
5 coding sequence to be transcribed by the promoter region
sequence. A promoter region would be operably linked to a
DNA sequence if the promoter were capable of effecting
transcription of that DNA sequence. Thus, to express the
protein, transcriptional and translational signals recognized
10 by the host cell are necessary.

A promoter is a double-stranded DNA or RNA molecule which is capable of binding RNA polymerase and promoting the transcription of an "operably linked" nucleic acid sequence. As used herein, a "promoter sequence" is the sequence of the 15 promoter which is found on that strand of the DNA or RNA which is transcribed by the RNA polymerase. A "promoter sequence complement" is a nucleic acid molecule whose sequence is the complement of a "promoter sequence." Hence, upon extension of a primer DNA or RNA adjacent to a single-20 stranded "promoter sequence complement" or, of a "promoter sequence," a double-stranded molecule is created which will contain a functional promoter, if that extension proceeds towards the "promoter sequence" or the "promoter sequence complement." This functional promoter will direct the 25 transcription of a nucleic acid molecule which is operably linked to that strand of the double-stranded molecule which contains the "promoter sequence" (and not that strand of the

molecule which contains the "promoter sequence complement").

The promoter sequences useful for producing cells
for the present invention may be either eukaryotic or viral.
Suitable promoters are repressible, or, more preferably,
constitutive. Useful eukaryotic promoters include the
promoter of the mouse metallothionein I gene (Hamer, D., et
al., J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of
Herpes virus (McKnight, S., Cell 31:355-365 (1982)); the SV40
early promoter (Benoist, C., et al., Nature (London) 290:304310 (1981)). A preferred promoter, in particular for human
fibroblasts, is the collag n promoter (Prockop, D.J. et al.,

N. Eng. J. Med. 301:13-23, 77-85 (1979); Eyre, D.R., Science 207:1315-1322 (1980); Martin, G.R. et al., Trends Bioch. Sci. 10:285-287 (1985); which references are hereby incorporated by reference).

Also intended within the scope of the present invention are cells attached to a support matrix, according to the invention, which are frozen and stored in a frozen state using methods well known in the art. Following thawing, the matrix-bound cells are implanted into a recipient brain.

The cells useful in the methods of the present invention may be xenogeneic (= heterologous, i.e., derived from a species different from the recipient), allogeneic (= homologous, i.e., derived from a genetically different member of the same species as the recipient) or autologous, wherein the recipient also serves as the donor.

The number of cells needed to achieve the purposes of the present invention is variable depending on the size, age, weight of the subject, the nature of the underlying 20 disease, other concurrent therapies, and the like. This can be determined by one of skill in the art without undue experimentation. In an adult human, an effective number of cells attached to a support matrix are in the range of about 1 x 10³ to about 1 x 10⁷ cells, more preferably about 5 x 10³ to about 1 x 10⁶ cells. Alternatively, the effective amount of transplanted cells can be determined in terms of mass of cells added to a volume of beads, for example 40 mg of cell mass per ml of beads.

. ...

Materials of which the support matrix can be

30 comprised include those materials to which cells adhere
following in vitro incubation, and on which cells can grow,
and which can be implanted into a mammalian brain without
producing a toxic reaction, or an inflammatory or gliosis
reaction which would destroy the implanted cells or otherwise

35 interfere with their biological or th rapeutic activity.
Such materials include, but ar not limited to, glass and
other silicon oxides, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyur thane, polyalginate,

polysulphone, polyvinyl alc hol, acrylonitrile polymers, polyacrylamid, polycarbonate, polypentene, nylon, amylases, gelatin, collagen, natural and modified polysaccharides, including dextrans and celluloses (e.g. nitrocellulose), agar, and magnetite. Either resorbable or non-resorbable materials may be used.

The support matrix of the present invention is distinguished from that described by Aebischer and his colleagues (see above) in that, according to the present 10 invention, the cells are attached to the outer surface of the support; they are not encapsulated within a closed compartment, where their survival would be questionable given the exclusion capacity of the disclosed encapsulating supports. Furthermore, the support matrix of the present invention 15 presents no requirement that the material have particular permeability properties, such as the selective permeability of the Aebischer devices which allow low molecular weight substances to cross but exclude larger molecules (>50 kD).

The configuration of the support is preferably 20 spherical, as in a bead, but may be cylindrical, elliptical, a flat sheet or strip, a needle or pin shape, and the like. A preferred form of support matrix is a glass bead. Another preferred bead is a polystyrene bead. Bead sizes may range from about 10 μm to 1 cm in diameter, preferably from about 25 90 to about 150 μm . For a description of various microcarrier beads, see, for example, Fisher Biotech Source 87-88, Fisher Scientific Co., 1987, pp. 72-75; Sigma Cell Culture Catalog, Sigma Chemical Co., St. Louis, 1991, pp. 162-163; Ventrex Product Catalog, Ventrex Laboratories, 1989; these 30 references are hereby incorporated by reference. The upper limit on the bead size is dictated by the bead's stimulation of undesired host reactions such as gliosis, which may interfere with the function of the transplanted cells or cause damage to the surrounding brain tissue. Such limita-35 tions are readily determinable by one f skill in the art.

To improve c 11 adhesion, survival and function, the solid matrix may optionally b coated on its external surface with factors known in the art to promote cell

adh sion, gr wth or survival. Such factors include cell adhesion molecules, extracellular matrix, such as, for example, fibronectin, laminin, collagen, elastin, gycosaminoglycans, or proteoglycans (see: Albers, B. supra, pp. 802-5834) or growth factors, such as, for example, NGF. Alternatively, if the solid matrix to which the implanted cells are attached is constructed of porous material, the growth- or survival-promoting factor or factors may be incorporated into the matrix material, from which they would be slowly released after implantation in vivo.

In an alternate embodiment of the present invention, cells growing on resorbable matrices, such as, for example, collagen, can be implanted in sites of neurological interest other than the brain, in order to promote neuronal regrowth or recovery. For example, cells attached to the matrix of the invention may be implanted into the spinal, cord, or placed in or adjacent to the optic nerve.

The methods of the present invention are useful for treating a number of human neurological disease. Parkinson's 20 Disease can be treated according to the present invention by implanting dopamine-producing cells in the recipient's striatum. Alzheimer's disease (AD) involves a deficit in cholinergic cells in the nucleus basalis. Thus, according to the invention, a subject having AD or at risk therefor may be implanted with cells producing acetylcholine.

Huntington's disease involves a gross wasting of the head of the caudate nucleus and putamen, usually accompanied by moderate disease of the gyrus. A subject suffering from Huntington's disease can be treated by implanting cells producing the neurotransmitters gamma amino butyric acid (GABA), acetylcholine, or a mixture thereof. According to the present invention, the support matrix material to which such cells are attached is preferably implanted into the caudate and putamen.

Epilepsy is not truly a single disease but rather is a symptom produced by an underlying abnormality. One skilled in the art will appreciate that each epileptic subject will have damage or epileptic foci which are unique

treatm nt, the pr paration was shaken gently by bubbling through 99.9% O_2 . After digestion, the tissue was washed three or four times with the above salt solution and then triturated gently in a pasteur pipet.

- The dissociated chromaffin cells were transferred to cell culture flasks containing serum free medium (Ventrex PC 1) and were cultured overnight at 37°C in a 5% CO₂ atmosphere. Under these conditions, the cells retain their viability for no more than a few days. Sterilized glass
- 10 beads (Ventrex, 90 micron) were added to the culture flask. The cells attached to the beads and essentially formed a monolayer on the beads. Within 24 hrs. of preparation in vitro, 1 to 5 μl aliquots of the cell-carrying bead suspension were injected into the brains of anesthetized
- 15 adult rats. Later analysis, at times when the cells would not have survived in culture, the cells were found to be viable in vivo in the site surrounding the injection, (see Figure 1) as determined by immunocytochemical staining for tyrosine hydroxylase according to the Weiner procedure (see:
- 20 Kilpatrick, D.L. et al., J. Neurochem. 35:679 (1980);
 Hokfelt, R. et al., Handbook of CHemical Neuroanatomy,
 Elsevier Science Publishers, Amsterdam (1985)). The glass
 beads produced no necrotic damage above that typical of the
 injection itself.

25

EXAMPLE II

Adrenal medullae were removed from adult guinea pigs according to methods described in Example I and subjected to the procedure described in Example I. The cells on glass microbeads were injected into rat brain. The cells survived for a period of at least 21 days in a completely healthy state. No signs of immunological rejection were evident.

EXAMPLE III

Cultur d human foreskin fibroblasts were attached 35 t glass microbeads as described above and injected into the rat brain. The cells were localized by immunofluorescence

using human IgG which selectively bound to the fibroblasts, followed by a fluor scein-conjugat d goat anti-human IgG antibody. The implanted human cells survived for a period of at least 21 days in a completely healthy state. No signs of immunological rejection were evident.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and 20 as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation.

WHAT IS CLAIMED IS:

- A method for grafting a cell in the brain of a mammalian subject comprising attaching said cell to the outer surface of a support matrix <u>in vitro</u> and implanting said
 support matrix with said attached cell into said brain.
 - 2. The method of claim 1 wherein said support matrix is a microbead.
 - 3. The method of claim 2 wherein said microbead has a diameter from about 90 to about 150 $\mu m\,.$
- 4. The method of claim 1 wherein said support matrix is made of a material selected from the group consisting of silicone oxide, polystyrene, polypropylene, polyethylene, polycarbonate, polypentene, acrylonitrile polymer, nylon, natural polysaccharide, modified polysaccharide, amylase, collagen, natural cellulose, modified cellulose, agar and magnetite.
 - 5. The method of claim 4 wherein said support matrix is silicon oxide.
- 6. The method of claim 1 wherein said cell is of 20 neural or paraneural origin.
 - 7. The method of claim 6 wherein said cell is an adrenal chromaffin cell.
 - 8. The method of claim 1 wherein said cell is a retinal pigment epithelial cell.
- 9. The method of claim 1 wherein said cell is from a cell line cultured in vitro.
 - 10. The method of claim 9 wherein said cultur d cell is a fibroblast.

- 11. The method of claim 9 wherein said cultured cell has been genetically modified by transfection of genetic material encoding a protein or proteins rendering said genetically modified cell capable of producing a neurotrans5 mitter substance or a neuronal growth factor.
 - 12. A method for treating a neurological disease in a subject comprising grafting into the brain of said subject an effective number of cells capable of treating said disease according to the method of claim 1.
- 13. The method of claim 12 wherein said disease is selected from a group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain injury.

FIG. I



International Application No.

According to International Planta Classification (IPC) or to each National Classification and IPC U.S. C1: 424/93, 423, 529, 569, 570, 574: 435/240.23, 240.24 IPC(5): A61K 37/00; C12N 5/00 IF PELOS SEARCHED Minimum Documentation Searches 424/93, 423, 433, 520, 529, 563, 570, 574; 435/740, 176, 177, 179, 180, 240, 1, 240, 2, 240, 23, 240, 24; 604/891.1: 935/62, 71 Obcumentation Searches street than Minimum Documentation in the Eutent man such Documents are included in the Fields Searches 4 MEDLINE, BIOSIS III. DOCUMENTS COMBIDERD TO BE RELEVANY! Calegory Cristion of Document, "with indication, where approximate, of the resevant baseages "U.A., 6, 7, 9, 2, 33, 5 Y. U.S. A. 4, 980, 553 (Silver et al.) issued 13 I. 4, 6, 7, 9, 2, 33, 5 Y. U.S. A. 4, 748, 121 (Beaver et al.) issued 31 Ray 1988, see the entire document. Y. Hidrocarrier Culture: A Hoodement. Y. Hidrocarrier Culture: A Hoodementument of the International Translation," pages 184-186, see the entire document. Y. Science, Volume 242, issued 16 Document - Special Categories of cred documents." Y. Science, Volume 242, issued 16 Document Y. Science, Volume 242, issued 16 Document Y. Science, Volume 242, issued 16 Document - Special Categories of cred documents." Y. Science, Volume 242, issued 16 Document - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categories of cred documents. " - Special Categories of cred documents." - Special Categor	I. CLASS	SIFICATE N F SUBJECT MATTER (if several classification symbols apply, indicate all) 6		
### PRECOS SEARCHED Minimum Documentation Searched Classification System Classification System Classification System Classification System Classification System Classification System 424/93.423.433.520.529.563.570.574;	According to International Patent Classification (IPC) or to both National Classification and IPC			
Classification System Classification Sympols	U.S. C1: 424/93,423,529,563,570,574; 435/240.23,240.24			
Classification System U.S. 424/93,423,433,520,529,563,570,574; 435/74,176,177,179,180,240,1,240,2,240,23,240,24; 604/891.1; 935/62,71 Decumentation Searched other than Minimum Documentation to the Literal that such Documents are included in the Friedle Searched 1 MEDLINE, BIOSIS M. DOCUMENTS COMBIDERED TO BE RELEVANT* Classor* Classor* Classor of Document, 1 with instable, mere supreprints, of the retwant passages 1 Y. U.S. A, 4,980,553 (Silver et al.) issued 13 L.4,6,7.9, 2.3,5 Y. U.S. A, 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y. Hethods in Enzymology, Volume LVIII, Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochesiatry*, pages 184-186, see the entire document. Y. Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Hodified of Cells to the Damaged Brain: Reatorative Effects of MSF Expression," pages 1975-1977, see entire document. Y. JiS, A, 4,892,538 (Arbischer et al.) 99 1-13 * Special categories of crise documents: " * Special categor	IPC(5): A61K 37/00; C12N 5/00			
U.S. 424/93,423,423,520,529,563,570,574; 435/74,176,177,179,180,240.1,240.2,240.23,240.24; 604/891.1; 935/62,71 Decumentation Searched other than Minimum Documentation to the Estant Interest Consequence of the Interest Consequence o	II FIELDS SEARCHED			
U.S. 424/93,423,433,520,529,563,570,574; 435/74,176,177,179,180,240.1,240.2,240.23,240.24; 604/891.1; 935/62,71 Decumentation Searched other than Minimum Documentation to the Elish that each Occuments are included in the Fields Searched ! MEDLINE, BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT* Citiegery* Citation of Document. "I with indication, where supragnists, of the relevant bassages "I Relevant to Claim No." Y US, A, 4,969,553 (Silver et al.) issued 13	Minimum Documentation Searched 7			
A 435/74,176,177,179,180,240.1,240.2,240.23,240.24; 600/891.1; 935/62.71 Documentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fields Searched. MEDLINE, BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT: Cistopry! Citation of Document. It with indication, where appropriate, of the retervant passages II	Classification System Classification Symbols			
A 435/74,176,177,179,180,240.1,240.2,240.23,240.24; 600/891.1; 935/62.71 Documentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fields Searched. MEDLINE, BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT: Cistopry! Citation of Document. It with indication, where appropriate, of the retervant passages II	l	/2//02 /22 /22 520 520 562 570 57/		
MEDLINE. BIOSIS MEDLINE. Columnent. "with indication. where approximate. of the relevant passages " We call the second of Decument. "with indication. where approximate. of the relevant passages " We have a second of the seco	U.S.			
Decumentation Searched other than Minimum Decumentation to the Estent that such Documents are included in the Fields Searched 1 MEDLINE. BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT 1 Category 1	""		4;	
MEDLINE, BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT* Cition* Cition of Document. If with indication, where appropriate of the relevant bassages V X US, A, 4, 998, 553 (Silver et al.) issued 13 1, 4, 6, 7, 9, 2, 13 2, 3, 5 Y US, A, 4, 748, 121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII., Thilly et al., "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry*, pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of MGF Expression," pages 1573-1577, see entire document. Y Science acaseperes of cred documents.* Y LIS, A, 4, 892, 538 (Aebischer et al.) 99 1-13 * Special categories of cred documents.* To achiev decument but published on or effect the international filing date or entire document to the international filing date or entire document to other ascella reason its specified and eleganter creation or other ascella reason its specified and eleganter or other ascella reason its inspecified and eleganter or other ascella reason its specified and eleganter or other ascella reason its incitionation or other ascella reason its specified and eleganter or other ascella reason its incitionation or other ascella reason				
MEDLINE, BIOSIS III. DOCUMENTS CONSIDERED TO BE RELEVANT* Cistagory* Cistation of Occument. "I with indication, where appropriate, of the revent passages "I Revent to Claim No. "I X US. A. 4,900,553 (Silver et al.) issued 13 1,4,6,7,9, 12,13 2,3,5 Y US. A. 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII., Thilly et al., "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression:" pages 1575-1577, see entire document. Y Lis, A, 4,892,538 (Aebischer et al.) 09 1-13 *Special categories of cried documents: " *A document defining ine general state of the art affect is not considered to be all particular reference to the international defining date of secundar reference in the Commendation of the Commendat				
Calegory Cristion of Document. With indication, where appropriate, of the relevant bassages Relevant to Claim No.	l	to the Estent that such Documents are included in the Freits Searched		
Calegory Cristion of Document. With indication, where appropriate, of the relevant bassages Relevant to Claim No.	ł			
Calegory Cristion of Document. With indication, where appropriate, of the relevant bassages Relevant to Claim No.	l ME	THE RECETS		
US. A, 4,960,553 (Silver et al.) issued 13 Y February 1990, see the entire document. Y US. A, 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y US. A, 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII, Thilly et al., "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Hodified Cells to the Damaged Brain: Restorative Effects of MGF Expression," pages 1575-1577, see entire document. Y US, A, 4,892,538 (Aebischer et al.) 99 1-13 -* Special categories of cited documents: " -A' document defining the general state of the art which is not considered to be of particular relevance T' decement expects by substitute on a effect the international fining date -Y document which may three daughts on specified in considered to be of particular relevance -Y decement which may three daughts on specified in considered to be of particular relevance in the comment of cannot be considered in the principle of comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of the comment of the co	. "11	EDEINE, BIOSIS		
US. A, 4,960,553 (Silver et al.) issued 13 Y February 1990, see the entire document. Y US. A, 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y US. A, 4,748,121 (Beaver et al.) issued 31 Hay 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII, Thilly et al., "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Hodified Cells to the Damaged Brain: Restorative Effects of MGF Expression," pages 1575-1577, see entire document. Y US, A, 4,892,538 (Aebischer et al.) 99 1-13 -* Special categories of cited documents: " -A' document defining the general state of the art which is not considered to be of particular relevance T' decement expects by substitute on a effect the international fining date -Y document which may three daughts on specified in considered to be of particular relevance -Y decement which may three daughts on specified in considered to be of particular relevance in the comment of cannot be considered in the principle of comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of comments of cannot be considered in the principle of comments of the comment of cannot be considered in the principle of the comment of the co	III DOCUMENTS CONSIDERED TO BE RELEVANT			
US. A. 4.900.553 (Silver et al.) issued 13 February 1990, see the entire document. VIS. A. 4.748.121 (Beaver et al.) issued 31 Hay 1988, see the entire document. VIS. A. 4.748.121 (Beaver et al.) issued 31 Hay 1988, see the entire document. VIS. A. 4.748.121 (Beaver et al.) issued 1979, Issued 1979, Hethods in Enzymology, Volume LVIII., Thilly et al "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Blochemistry", pages 184-186, see the entire document. VI Science, Volume 242, issued 16 December 1988, Rosenberg et al "Grafting Genetically Hoddfied Cells to the Damaged Brain: Restorative Effects of NGF Expression;" pages 1575-1577, see entire document. VI LIS. A. 4.892,538 (Aebischer et al.) 99 1-13 **Special categories of cried documents: " **A document defining the general tate of the ari which is not considered to be of particular relevance **A document defining the general tate of the ari which is not considered to be of particular relevance **Considered to a carbon decimance **Considered to be of particular relevance **Considered to a carbon decimance **Considered to be of particular relevance **Considered to be of particular relevance **Considered to be of particular relevance **Considered to a carbon decimance **Considered to a carbon decimance **Considered to a carbon dec			Relevant to Claim No. 12	
Y US, A, 4,748,121 (Beaver et al) issued 31 May 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII, Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression;" pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 89 1-13 **Specul categories of cited documents: " "A" document defining the general state of the ant which is not changed to be of particular researches." Tenner decument but published on or effect the international filing date "L' document destinate the published on or effect the international connected to be of particular invessments." "A" document which may throw doubts on shorter televisial or which is a cited to submission of other special relevance; the claimed invention cannot be considered moved or cannot be considered with one a removable state of service and service considered in the state of service and the considered with one a removable state of service and the considered with one are more other such documents and the state of service and the considered with one are more other such documents and considered with one are more other such documents and considered with one are more other such documents and the state of services and more of services and more other such documents and the state of services and more other such documents and the state of services and more other such documents and more other such documents and more other such documents and services and more other such documents and services and services and more other such documents and more other such documents and more other suc	Category	Citation of Gocaman, With Materials, 4 and 6 app.		
Y US, A, 4,748,121 (Beaver et al) issued 31 May 1988, see the entire document. Y Hethods in Enzymology, Volume LVIII, Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression;" pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 89 1-13 **Specul categories of cited documents: " "A" document defining the general state of the ant which is not changed to be of particular researches." Tenner decument but published on or effect the international filing date "L' document destinate the published on or effect the international connected to be of particular invessments." "A" document which may throw doubts on shorter televisial or which is a cited to submission of other special relevance; the claimed invention cannot be considered moved or cannot be considered with one a removable state of service and service considered in the state of service and the considered with one a removable state of service and the considered with one are more other such documents and the state of service and the considered with one are more other such documents and considered with one are more other such documents and considered with one are more other such documents and the state of services and more of services and more other such documents and the state of services and more other such documents and the state of services and more other such documents and more other such documents and more other such documents and services and more other such documents and services and services and more other such documents and more other such documents and more other suc	!		l <u>-</u> -	
US, A, 4.748,121 (Beaver et al) issued 31 May 1988, see the entire document. Y Hethods in Enzysology, Volume LVIII, Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression," pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) Tanuary 1990, see entire document "A" document defining the general state of the an which is not restorated to be all particular state of the an which is not restorated to be all particular state of the antendenced in the cites te scales in the published on promy claimfal or which is cited to establish the published on or other contended or	X	US, A, 4,900,553 (Silver et al.) issued 13		
Y US, A, 4,748,121 (Beaver et al) issued 31 Hay 1988, see the entire document. Second 1979, Hethods in Enzymology, Volume LVIII., Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression." pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 99 1-13 *Special categories of cited documents: " *A document defining the general size of the sri which is not considered to be a particular researce T' eacher decument but sublished en or after the international filing date cited to enderstand the principles of investment of approxical research (as a specified) T' decument which may throw doubts on shorter claimed investment of semicone or other special research (as specified) T' decument relations from the control of special research (as specified) T' decument relations from the control of special research (as specified) T' decument relations from the semicone or other means: "T' decument sublished and or after the international filing date but invested an investment size of the semicone with one or more other such document of commons with one or more other such document of commons and the means of the such document of commons and the means of the such document of commons and common to common and common to common and common to common and common	Y	February 1990, see the entire document.	12.13	
Y US, A, 4,748,121 (Beaver et al) issued 31 Hay 1988, see the entire document. Second 1979, Hethods in Enzymology, Volume LVIII., Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression." pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 99 1-13 *Special categories of cited documents: " *A document defining the general size of the sri which is not considered to be a particular researce T' eacher decument but sublished en or after the international filing date cited to enderstand the principles of investment of approxical research (as a specified) T' decument which may throw doubts on shorter claimed investment of semicone or other special research (as specified) T' decument relations from the control of special research (as specified) T' decument relations from the control of special research (as specified) T' decument relations from the semicone or other means: "T' decument sublished and or after the international filing date but invested an investment size of the semicone with one or more other such document of commons with one or more other such document of commons and the means of the such document of commons and the means of the such document of commons and common to common and common to common and common to common and common			0 3 5	
1988, see the entire document. Y			F.3.3	
1988, see the entire document. Y		US. A. 4.748.121 (Beaver et al) issued 31 May		
Y Hethods in Enzymology, Volume LVIII., Thilly et al., "Microcarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y Science, Volume 242, issued 16 December 1988, Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression." pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 89 1-13 **Special categories of cited documents: "The document defining the general state of the entire document. **Special categories of cited documents: "The document defining the general state of the entire document. **Special categories of cited documents: "The document defining the general state of the entire document. **Special categories of cited documents: "The document defining the general state of the entire document. **Special categories of cited documents: "The document defining the general state of the entire document. **The document defining the general state of the entire document. **The document defining the general state of the entire international fining data or general deciment the process of cited documents: "The comment defining state and only in confect with non-confect or considered to be elegated in the process of another confect or considered to restorate international connect to considered to restorate international connect to considered to restorate international connect to considered to restorate an invention and invention accounted to restorate a invention connect to considered to restorate an invention of confect with non-connect and invention accounted to restorate a invention connect to connected to restorate an invention and invention accounted to restorate a invention and invention accounted to restorate an invention and invention and invention and invent	Y	·	5	
Hethods in Enzymology, Volume LVIII, AThilly et al., "Hicrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y				
al., "Ricrocarrier Culture: A Homogeneous Environment for Studies of Cellular Biochemistry", pages 184-186, see the entire document. Y				
Environment for Studies of Cellular Biochesistry*, pages 184-186, see the entire document. Y	Y		1-13	
Biochemistry*, pages 184-186, see the entire document. Y				
Science, Volume 242, issued 16 December 1988, Rosenberg el al., "Grafting Genetically Hodified Cells to the Damaged Brain: Restorative Effects of NGF Expression," pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 99 1-13 "Special categories of cited documents: " "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" decument which may throw doubts on priority claims) or which is cited to establish the publication atto of another contains a considered need or cannot be considered to involve an involve and involve	1	•		
Science, Volume 242, issued 16 December 1988, Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression," pages 1575-1577, see entire document. Y = US, A, 4,892,538 (Aebischer et al.) "Special categories of cited documents: " "A" document defining the general state of the sri which is not considered to be el particular resewance "T" eather decument but published on enter the international filing date "I" decument which may throw doubts on enter the international filing date "I" decument which may throw doubts on enter the international filing date of the street decument of assistance of international research respectal research its specified) "O" decument referring to an oral disclesure, use, eshibition or other means: "P" decument sublished error to the international filing date but later than the proving date chained invention cannot be considered in which is cleared an enter the considered in which is cleared an enter the cleared invention cannot be considered in which is cleared invention at an enter the considered in which is decument referring to an oral disclesure, use, eshibition or other means: "P" decument evolutioned error to the international filing date but later than the published error to the international filing date in the est. "A" document of ashibition or other sound an expectation but international cannot be considered in whole as invention cannot be considered in whole as invention and the commence size of annotation of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Discount of Authorized Officer Separative of Authorized Officer		Biochemistry", pages 184-185, see the entire	•	
Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression." pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) "Special categories of cited documents: "9 "A document defining the general size of the art which is not Considered to be of particular relevance "E" carrier document but published en or after the international filting date "L" document which may throw doubts on priority claimed; "C" decument which may throw doubts on priority claimed; "O" decument referring to an oral disclessure, use, eshabition or other means "P" decument subhished priority date claimed "IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 Impressional Authority TO FEB 1992 Impressional Authority To the complete of completion of Authority To the complete of the International Search Report 10 FEB 1992 Impressional Authority		document.		
Rosenberg el al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression." pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) "Special categories of cited documents: "9 "A document defining the general size of the art which is not Considered to be of particular relevance "E" carrier document but published en or after the international filting date "L" document which may throw doubts on priority claimed; "C" decument which may throw doubts on priority claimed; "O" decument referring to an oral disclessure, use, eshabition or other means "P" decument subhished priority date claimed "IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 Impressional Authority TO FEB 1992 Impressional Authority To the complete of completion of Authority To the complete of the International Search Report 10 FEB 1992 Impressional Authority				
Cells to the Damaged Brain: Restorative Effects of NGF Expression," pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) 69 Tanuary 1990, see entire document. *Special categories of cited documents: 19 "A" document defining the general state of the art which is not considered to be of particular relevance of the entire filting date of the processor of the entire filting date of the entire filti	Y	Science, Volume 242, issued 16 December 1988,	1-13	
of NGF Expression:" pages 1575-1577, see entire document. Y - US, A, 4,892,538 (Aebischer et al.) * Special categories of cited documents: " *A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier decument but published on or after the international filing date or priority date and not in conflict with the application but subscissed the publication of which is cited to establish the publication of which is cited to establish the publication of cited of another citation or other special reason (as specified) "O" decument subsished prior to the international filing date of other meens "P" decument subsished prior to the international filing date of the actual comment of particular relevance: the claimed invention cannot be considered to inventive step when the comment subsished in early date claimed "Y. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority TV CERTIFICATION Date of the Actual Completion of the International Search 10 FEB 1992 Improve of Authorized Officer		Rosenberg el al., "Grafting Genetically Modified		
"Special categories of cited documents: "9 "A" document defining the general state of the art which is not created document but subhished after the international filing date of pharticular relevance "E" earlier document but subhished on or after the international filing date of pharticular relevance in created to be eliparticular relevance in accument place and not in conflict with the application out create to subhished after the international filing date of pharticular relevance; the claimed invention created to subhished enter the international or which is cited to establish the publication date of another created to invention or other absent in assent (as assential) "O" document referring to an oral disclosure, use, ashibition or other mains "P" document relearing to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the international Search 23 January 1992 Improved Imp		Cells to the Damaged Brain: Restorative Effects		
Y - US, A, 4,892,538 (Aebischer et al.) 1-13 * Special categories of cited documents: ** *A" document defining the general siste of the art which is not considered to be all particular relevance Tell estere document but published on or after the international filling date "L" document which may throw doubts on enterty claim(s) or which is cited to establish the publication acts of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, eshibition or other means "P" document subhished error to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the international Search 23 January 1992 International Searching Authority TO FEB 1992 International Searching Authority		of NGF Expression," pages 1575-1577, see entire		
* Special categories of cited documents: ** * ** ** ** document defining the general state of the art which is not cited to be of particular relevance *** ** ** arriver decument but published on or after the international filing date or enterty date and not in conflict with the application but cited to be of particular relevance *** *** ** ** ** *** *** *** *** ***		· · · · · · · · · · · · · · · · · · ·		
* Special categories of cited documents: ** * ** ** ** document defining the general state of the art which is not cited to be of particular relevance *** ** ** arriver decument but published on or after the international filing date or enterty date and not in conflict with the application but cited to be of particular relevance *** *** ** ** ** *** *** *** *** ***			·	
* Special categories of cited documents: ** * ** ** ** document defining the general state of the art which is not cited to be of particular relevance *** ** ** arriver decument but published on or after the international filing date or enterty date and not in conflict with the application but cited to be of particular relevance *** *** ** ** ** *** *** *** *** ***	Y _	US. A. 4.892.538 (Aebischer et al.) 09	1-13	
* Special categories of cited documents: 19 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier decument but published on or after the international filing date "L" document which may throw doubts on enority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, eshibition or other means "P" document sublished error to the international filing date but later than the priority date claimed 19. CERTIFICATION Date of the Actual Completion of the international Search 23. January 1992 International Searching Authority "T later document sublished after the international filing date or short is not in conflict with the aspication but crited to underly date in enternational filing date or short to considered in the claimed invention cannot be considered in enterior or cannot be considered in excession as or cannot be considered in enterior or cannot be considered in excession as approach as a particular relevance; the claimed invention and invention are considered in excession as approach as a particular relevance; the claimed invention are considered in excession as a particular releva	1 -		1-12	
"A" document defining the general state of the art which is not considered to be of particular relevance." "E" earlier decument but published on or after the international filing date. "L" decument which may throw doubts on priority claim(s) or which is cited to establish the publication este of another citation or other special respond (as specified). "O" document referring to an oral disclosure, use, eshibition or other means. "P" decument subhished prior to the international filing date but later than the priority date claimed. IV. CERTIFICATION. Date of the Actual Completion of the international Search. 23 January 1992. International Searching Authority. The document of particular relevance; the claimed invention cannot be considered need or cannot be considered in invention of anticular relevance; the claimed invention of an				
"A" document defining the general state of the art which is not considered to be of particular relevance." "E" earlier decument but published on or after the international filing date. "L" decument which may throw doubts on priority claim(s) or which is cited to establish the publication este of another citation or other special respond (as specified). "O" document referring to an oral disclosure, use, eshibition or other means. "P" decument subhished prior to the international filing date but later than the priority date claimed. IV. CERTIFICATION. Date of the Actual Completion of the international Search. 23 January 1992. International Searching Authority. The document of particular relevance; the claimed invention cannot be considered need or cannot be considered in invention of anticular relevance; the claimed invention of an				
"A" document defining the general state of the art which is not considered to be of particular relevance." "E" earlier decument but published on or after the international filing date. "L" decument which may throw doubts on priority claim(s) or which is cited to establish the publication este of another citation or other special respond (as specified). "O" document referring to an oral disclosure, use, eshibition or other means. "P" decument subhished prior to the international filing date but later than the priority date claimed. IV. CERTIFICATION. Date of the Actual Completion of the international Search. 23 January 1992. International Searching Authority. The document of particular relevance; the claimed invention cannot be considered need or cannot be considered in invention of anticular relevance; the claimed invention of an	l <i></i>			
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier decument but published on or after the international filling date. "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other apocial reason (as apocified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" decument subhished prior to the international filling date but later than the priority date claimed. "V. CERTIFICATION. Date of the Actual Completion of the International Search. 23 January 1992. International Searching Authority. Cited to unserstand the principle or theory underlying the citive to invente in invente in the cannot be considered; the claimed invention cannot be considered to invente an invente an invention and cannot be considered to invente an invention of another means. "Y" document of particular relevance; the claimed invention cannot be considered in invente an invention of accument relevance; the claimed invention cannot be considered to invente an invention of accument relevance; the claimed invention cannot be considered in invente an invention of accument relevance; the claimed invention cannot be considered in invente an invention of accument relevance; the claimed invention cannot be considered in invente an inventive an in	or analys date and not in conflict with the apprecation out			
"E" earlier decument but published on or after the international filing date "L" document which may throw doubts on priority claimts) or which is cited to establish the publication este of another cristian or other special resen (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" decument sublished prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority "X" document of sarticular relevance; the claimed invention cannot be considered to inventive stap when the document is combined with one or more other such documents, such commission being obvious to a person skilled in the art. -4" document of particular relevance; the claimed invention cannot be considered to inventive stap when the document is combined in the such commission being obvious to a person skilled in the art. -4" document of particular relevance; the claimed invention cannot be considered to considered to inventive stap under the considered to inventive stap under the same person skilled in the art. -4" document of particular relevance; the claimed invention cannot be considered to considered to inventive stap under the considered to inventive stap under the same person skilled in the art. -4" document of particular relevance; the claimed invention cannot be considered to considered to inventive stap under the	"A" dod	tument defining the general state of the art which is hele cities to understand the principle	or theory underlying the	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another critation or other assess (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" decument sublished prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Cannot be considered nevel or cannot be cansidered nevel or cannot be considered in the set which an inventive stap under the cannot be considered in the cannot be considered to the claimed inventive stap under the cannot be considered nevel or cannot be considered in the cannot cannot be considered in the cannot cannot be considered nevel or cannot be considered in the cannot be added in the cannot be considered in the cannot be consid	"E" serior document but published on or after the international -x- document of perbular relevance; the claimed invention			
which is cited to establish the publication este of another citation or other apocial resean (as specified) "O" document referring to an oral disclosure, use, eshibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority "Y" document of particular relevance; the claimed invention cannot only occurrent a comment of particular relevance; the claimed invention cannot be considered in which the process such documents are considered in the same patient family "Y" document of particular relevance; the claimed invention cannot be considered in which the cannot be operated and comments. Such comments on the same patient family TV. CERTIFICATION Date of Making of this International Search Report 10 FEB 1992 International Searching Authority Signature of Authorized Officer	filing date cannot be considered nevel or cannot be considered to			
"O" decument referring to an oral disclosure, use, exhibition or other machs "P" decument sublished prior to the international filing date but later than the priority date claimed IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Signature of Authorized Officer	which is cited to establish the publication date of another "Y" deciment of particular relevance; the claimed invention			
other meens "P" decument subhished error to the international filing date but in the art. -a" escument member of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Signature of Authorized Officer	citation or other special reason (as specimes) cannot be considered to involve an inventive step when the			
"P" decument sublished error to the international filing date but ster than the priority date claimed "A" excument member of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Signature of Authorized Officer	other means such combination being elevious to a person skilled			
IV. CERTIFICATION Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Signature of Authorized Officer	-P- de	cument published prior to the international filing date but	etent Ismiy	
Date of the Actual Completion of the International Search 23 January 1992 International Searching Authority Date of Making of this International Search Report 10 FEB 1992 Signature of Authorized Officer		William the property control of the		
23 January 1992 International Searching Authority Signature of Authorized Officer	The state of the s			
Imernational Searching Authority Signature of Authorized Officer	Date of th	A A	BICH REPORT	
Imernational Searching Authority Signature of Authorized Officer	22 1	10 FER 1992		
Motore	- 23 J			
	Internatio	net Sperching Admirally		
Jacqu line M. Stone	TCA			
	13K/	Jacqu line M. Stone		

THIS PAGE BLANK (USPTO)